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In November 2007, I started PhD three years course in Pharmaceutical 
Sciences at the Department of Pharmaceutical Sciences of University of 
Salerno under supervision of Prof. Ines Bruno. 
My PhD project was focused on design and synthesis of molecules potentially 
able to inhibit the microsomal prostaglandin E2 synthase (mPGES-1), a crucial 
enzyme involved in the last step of the arachidonic acid cascade. Specifically, 
as first task of my research I developed a small collection of molecules 
potentially able to inhibit the expression of the target enzyme, whereas in the 
second part I focused the attention on the realization of molecules potentially 
able to directly inhibit the activity of mPGES-1. The entire research work was 
carried out under the direct supervision of Prof. Ines Bruno.  
The collections mentioned above were designed taking advantages of 
professor Giuseppe Bifulco’s experience in molecular modeling-based 
approaches. Finally, to assess the bioactivity of the synthesized compounds, I 
joined forces of professors Miguel Paya and Oliver Werz from the University 
of Valencia and Tuebingen, respectively, that were involved in the biological 
assays.  
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Microsomal prostaglandin E2 synthase-1 (mPGES-1) is the enzyme 
responsible for the conversion of the cyclooxygenase (COX)-derived 
prostaglandins (PG)H2 into PGE2. This enzyme is deeply involved in different 
pathologies; in fact it is over-expressed in several inflammatory disorders as 
well as in some human tumours. Hence, the inhibition of mPGES-1 has been 
proposed as a promising approach for the development of safer drugs in 
inflammatory disorders, devoid of classical NSAID side effects. Indeed, this 
enzyme is responsible for the biosynthesis of inducible PGE2 as a response to 
inflammatory stimuli whereas it doesn’t affect constitutive PGE2 involved in 
crucial physiological functions. Today two are the main approaches employed 
in the inhibition of mPGES-1 activity. The first consists in the negative 
modulation of its expression, while the second one concerns the direct and 
selective inhibition of the enzyme.  
In order to identify novel molecules able to block mPGES-1, in the first part of 
this project we focused our attention on the design and synthesis of molecules 
able to inhibit the expression of our target enzyme. Specifically, as first task 
we decided to undertake the structural optimization of a γ-hydroxybutenolide 
related to petrosaspongiolide M (PM) 5, compound 6, that showed to be a 
potent negative modulator of mPGES-1 expression (IC50 = 1.80 µM). In the 
course of our investigation we identified two new hits that revealed an 
increased activity compared to the parent molecule 6, compounds 30 (IC50 = 
0.79 µM) and 31e (IC50 = 0.85 µM). Encouraged by these results, in order to 
amplify the chemical diversity of the γ-hydroxybutenolide scaffold and 
identify new lead structures able to inhibit mPGES-1 expression, we decided 
to develop a new collection of PM-derivatives featuring amido-aromatic 
portions linked to the γ-hydroxybutenolide scaffold. These compounds are 
currently under biological investigations whose outcomes could suggest new 
guidelines useful in the discovery of more effective agents. 
 




As second task, we concentrated our efforts on the development of molecules 
able to directly interfere with mPGES-1. Owing to the lack of its 
crystallographic structure in protein data bank (PDB), we decided to choose, 
as model for our investigations, microsomal glutathione transferase 1 (MGST-
1), an enzyme belonging to membrane associated proteins in eicosanoid and 
gluthatione metabolism (MAPEG) family and showing a high homology 
sequence with our selected target. On the basis of virtual screening outcomes, 
we designed and synthesized a collection of potential mPGES-1 inhibitors 
based on 1,4-disubstituted triazole moiety, a scaffold extensively employed in 
drug discovery that can be obtained through click chemistry approach, a 
powerful tool for the rapid exploration of the chemical universe based on 
practical and reliable chemical reactions. The biological evaluation of these 
compounds allowed us to individuate three new potential anti-inflammatory 
agents: (I) compound 54 displaying selectivity for mPGES-1 with an IC50 
value of 3.2 µM, (II) compound 70 that dually inhibits 5-lipoxygenase (5-LO) 
and mPGES-1 and (III) compound 57 acting as 5-lipoxygenase-activating 
protein (FLAP) inhibitor (IC50 = 0.4 µM).  
On the basis of these results, as last task of this project, we directed our 
attention on the new hit 54, emerged as a selective inhibitor of mPGES-1. In 
more details, on the basis of the suggestions coming from both the biological 
screening and the 3D model of interaction with MGST-1, aiming at improving 
its biological activity, we decided to rely on some well-reasoned structural 
changes of the basic molecule in order to enhance the binding affinity for the 
target enzyme. In this perspective, a new collection of triazole derivatives has 
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The improvement of the social-environmental conditions, medical care and 
quality of life, registered around the 1970s in all industrialized countries, 
caused a general enhancement of population health status and a consequent 
reduction of 1–2% per year of mortality and of the overall morbidity in 
individuals over 80 years old. Numerous epidemiological and clinical studies 
demonstrated that most of the disorders afflicting aged population, such as 
prostate and breast cancers, Alzheimer's disease and heart diseases, including 
atherosclerosis and clogged arteries, have their base in inflammation. 
Therefore it can be well understood the growing need of anti-inflammatory 
drugs devoid of the severe side effects connected with the chronic use of the 
commercially available anti-inflammatory drugs. Aspirin is the most used non 
steroidal anti-inflammatory drugs (NSAIDs) in the world for the treatment of 
several kinds of inflammatory diseases, but it is increasingly used for 
prophylaxis of vascular events, too. It is calculated that the percentage of 
people 65 years old or older, using NSAIDs at least once a week, has been 
reported to be as high as 70%, half of which takes at least seven doses a 
week.
[1]
 Unfortunately, an important factor limits the use of this class of 
molecules: their gastrointestinal and renal toxicity.
[2]
 To give an idea of the 
gravity of the NSAIDs side-effects, we can consider that a single dose of 
aspirin leads to gross gastric injury as subepithelial hemorrhages within 15–30 
minutes from the ingestion.
[3;4]
 After aspirin administration for 24 hours at 
dose of 650 mg four times a day, gastric erosions usually develop.
[3;5]
 In 
theory people taking aspirin develop gastric lesions in the first days of use.
 [2;3]
 
However, subepithelial hemorrhages and erosions do not cause major gastro-
intestinal bleeding or lead to other complications such as perforation or 
obstruction, that may develop within one week of regular NSAIDs administer. 
In fact, it is demonstrated that the incidence of gastroduodenal ulcers reaches 
25%–30% at three months and 45% at six months of continued administrations 
of this class of drugs.
[6]
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connected to the general suppression of constitutively formed prostanoids such 
as cyclooxygenase (COX)-1-derived cytoprotective prostaglandin (PG) E2 and 
prostacyclin (PGI2) in gastroduodenal epithelium. Indeed, even if PGE2 are the 
most prominent prostanoid in inflammation, fever and pain, they are also 




A solution of these problems seemed to derive at the end of ‟90 from the 
discovery of molecules able to selectively inhibit COX-2, the so called 
“coxibs”. This class of compounds able to selectively inhibit only PGE2 
produced by inflammatory stimuli, showed an improved gastrointestinal 
tolerance. Unfortunately, subsequent clinical studies revealed significant 
increased risk for cardiovascular events such as myocardial infarction, stroke, 
systemic and pulmonary hypertension, congestive heart failure and sudden 
cardiac death,
[8]
 apparently due to an imbalance of anti-thrombotic and 
vasodilatory PGI2 on one hand and pro-thrombotic thromboxane (Tx)A2 on the 
other hand. Therefore as inflammatory chronic pathologies, such as 
rheumatoid arthritis, require long-term drug application, side-effects represent 
a serious problem for therapy. This is the reason why, in recent years, there is 
an urgent need of efficient anti-inflammatory drugs that can be safely used in 
chronic inflammatory conditions. 
One of the most employed approach in pharmaceutical research today is the 
target-based drug discovery. It consists in the preliminary identification of the 
biological target involved in the pathology of interest and in the identification 
of agents able to selectively modulate the activity of this target. To satisfy 
these requirements several new technologies have been developed in order to 
both identify the protein and the potential ligands interfering with the 
macromolecule. Specifically, for example gene expression profiling can be 
employed to clarify the role played by a certain protein in the development and 
progression of a specific pathology.
[9]
 On the other hand, in order to discovery 
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molecules able to interact with this target, it is particularly useful to evaluate 
large libraries of compounds. At this regard extremely useful technologies, 
including combinatorial chemistry and high throughput screening (HTS) 
approaches, give us the possibility to increase the number of compounds to be 
tested and, consequently, the probability to identify active compounds.
[10]
 
Moreover, aimed at increasing discovery productivity in terms of time 
efficiency and cost reduction, virtual screening
[11]
 and structure-based drug 
design
[12]
 offer us the possibility to reduce the members of compounds need to 
be evaluated narrowing down the investigations to those compounds that, at 
least in theory, showed the higher binding affinity. Finally, a new approach, 
that has been successfully applied in drug discovery, is fragment-based drug 
design which allows the screening of smaller numbers of molecular fragments 
to identify low-molecular weight compounds that weakly bind the target 
macromolecule. Knowledge of how the fragments bind to the protein of 



























Chart 1. Chemical structures of bolinaquinone 1, scytonemin 2, topsentin 3 and 
debromohymenialdisine 4. 
Another more conventional approach in drug discovery starts from the 
consideration that the source of structurally unique molecules necessary for 
the drug discovery, is mainly accumulated in living organisms from terrestrial 
and marine environment. Hence the identification of new lead compounds 
within natural products appeared particularly promising also in the field of 
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have recently been discovered to display a remarkable anti-inflammatory 
activity.
[14]




 and the 
topsentins (e.g. 3)
[17]
 (Chart 1) have been extensively studied and represent 
interesting lead compounds for the development of promising anti-
inflammatory drugs, while debromohymenialdisine 4 (Chart 1) have been 




In particular a family of marine sesterterpenes containing a γ-
hydroxybutenolide moiety and showing a potent anti-inflammatory activity 
attracted our attention. Specifically, among this group of interesting sponge 
metabolites, petrosaspongiolide M (PM) 5 (Chart 2) emerged as a very 
promising molecule able to irreversibly inhibit phospholipase (PL) A2, the key 
enzyme involved in the inflammatory response.
[19;20]
 Through de novo design 
approaches and molecular modeling studies, focused collection of PM 
derivatives have been designed and synthesized by our research group with the 
aim of shedding more lights on the molecular mechanism of action and 
discovering new promising drug candidates. In the course of this project we 
identified several significant PLA2 inhibitors but the most relevant result was 
the discovery of 4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one 
6 (Chart 2) emerged as a potent selective inhibitor of microsomal 
prostaglandin E2 synthase-1 (mPGES-1) expression,
[21;22]
 a very promising 
target-enzyme involved in the last step of arachidonic acid cascade. On the 
basis of these premises we decided to embark in a new project focused on this 
relevant target. Indeed, mPGES-1 has recently been recognized as a very 
promising therapeutic target owing to its involvement in COX-2-dependent 
PGE2 biosynthesis induced during inflammation.
[23]
 Thereby, a selective 
inhibitor of this enzyme isoform has been supposed to block PGE2 generation 
connected to pathologies and to avoid the severe side-effects of the 
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commercially available anti-inflammatory drugs due to the massive 
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Chart 2. Chemical structures of petrosaspongiolide M (PM) 5 and its simplified 
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Inflammation is defined as the response to injuries of vascularized tissues to 
deliver blood cells and fluid at the side of damage. Three are the main 
problems caused by injuries: some vessels are severed, some tissue is 
destroyed and the door is open to invaders such as bacteria, viruses, fungi, 
worms and other parasites. The first problem, the bleeding, is critical but 
instantly solved by the local mechanism of hemostasis. The loss of the tissue, 
less urgent, will be compensated in a few days or weeks by regeneration, while 
local scavenger cells clear up the debris. The last problem, the infection, is 
critical also because the local defense is not adequate. In fact, the local 
antibacterial natural guard, present in the tissue, amounts to a few sleepy 
macrophages scattered among the fibroblasts that are not enough to ward off 
sudden bacterial attacks. However, the problem is solved thanks to defensive 
forces in the blood, where they circulate in inactive form and are activated in 
case of injury. Two are the main materials supplied by the inflammatory 
response: leukocytes, some of which are specialized for fighting bacteria, and 
plasma, which brings the defensive proteins. Plasma, indeed, contains 
opsonins, proteins that coat foreign materials and make them easier to be 
phagocytized. Moreover, there is a source of about twenty proteins, known as 
complement, which can be locally assembled to build a bacterial-performing 
machine, and antibodies that are able to recognize and bind the surface of 
bacteria or other unknown parasites. As a consequence of the arrival of cells 
and fluid to the place of injury, the inflamed part swells. In addition, as the 
local blood vessels dilate in order to speed up the delivery, the inflamed part 
becomes hot and red. On the basis of these considerations, we can confirm that 
four are cardinal signs of inflammation: redness and swelling with heat and 
pain (rubor et tumor cum calore et dolore). What is really interesting is that 
cells and fluid have to be extravasated without interrupting the blood flow. If 
we consider that extravasing blood cells are larger than red cells, we can 
understand that the organism needs of inflammation mediators able to create 
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the condition necessary for the travel of these important defenders to the site 
of injury. So, some mediators will instruct the endothelium to become leady 
and others will tell the leukocytes to stop and emigrate. What is nice is that the 
injured tissue itself produces the earliest mediators to appear on the scene of 
injury: the defense reaction is triggered by the product of the aggression. The 
mixture of leukocytes and plasma accumulated in the injured tissue is called 
exudates, while exudate in presence of cells, which are firstly leukocytes that 
phagocytized bacteria, is known as pus. It is easy to understand that 
inflammation lasts as long as required to eliminate the cause and to repair the 
damage. Obviously, with time, inflammation chances its characteristics. 
Specifically, vascular dilatation tends to subside and the redness 
correspondingly abates; moreover, the amount of fluid and the swelling 




On the basis of the time course, inflammations are classified in acute and 
chronic. Specifically, inflammation is defined acute if the event comes 
sharply, in hours or days, to a climax, while it is called chronic if the event 
persists for weeks, months or years. 
If we want to summarize the inflammatory response, we can consider it a cast 
of ten cells that are normally quiescent and become activated in the 
inflammatory focus. Every cell has subtype and can produce inflammatory 
mediators. Specifically, for example, while neutrophils are bacteria-killing 
machines, eosinophils are specific against worms. Moreover, macrophages are 
delegated to phagocytose cellular debris and pathogens and to stimulate 
lymphocytes and other immune cells responding to them. 
 
1.1.  Inflammatory mediators 
When leucocytes reach the site of injury thanks to the increased vessels 
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activation of others cells. Inflammatory mediators are small soluble molecules 
divided into two groups: external and endogenous mediators. The first ones 
are bacterial products and toxins, such as endotoxins and lipo-polysaccharides 
(LPS) produced by Gram negative bacteria. They cause the activation of the 
complement system and the consequent production of C3 and C5 
anaphylatoxins that are responsible for vasodilatation and enhanced vascular 
permeability. Moreover they can induce the activation of the Hageman factor 
involved in fibrin formation and coagulation. Differently from external 
mediators, the endogenous ones, such as histamine and platelet activating 
factor (PAF), are produced by immune system itself. As part of an immune 
response to foreign pathogens, histamine is produced by basophils and mast 
cells found in nearby connective tissues. Histamine increases the permeability 
of the capillaries to white blood cells and other proteins, in order to allow them 
to engage foreign invaders in the infected tissues. On the contrary PAF is 
produced in response to specific stimuli by a variety of cell types, including 
neutrophils, basophils, platelets and endothelial cells. It is a potent 
phospholipid activator and mediator of the inflammatory function of 
leukocytes and is responsible for the formation of exudate. 
Extremely important mediators in inflammatory events are eicosanoids, 
molecules derived from phospholipids, obtained thanks to the oxidation of 
long-chain polyunsaturated fatty acids. Coming from the autacoids family, 
eicosanoids derive from the arachidonic acid (Figure 1), a carboxylic acid with 
a 20-carbon chain and four cis double bonds, released from membrane 
phospholipids by different isoforms of PL enzyme (PLA2 and PLC). As 
described in Figure 1, arachidonic acid can be processed along two pathways: 
the COX pathway which leads to PGs, prostacyclins and Tx
[25]
 and 
lipoxygenase (LO) pathway which produces the leucotrienes.
[26]
 Each type of 
cell, appropriately stimulated by injury or other mediators, generates its own 
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particular choose of eicosanoids. For example, endothelium responds to 

















































































Figure 1. Arachidonic acid cascade: the pathway connected with inflammatory 
stimuli is underlined. 
 
In more details, 5-LO converts arachidonic acid into 5-
hydroperoxyeicosatetraenoic acid (5-HPETE), which spontaneously turns in 5-
hydroxyeicosatetraenoic acid (5-HETE). Successively, 5-LO itself converts 5-
HETE into leukotriene (LT) A4, an unstable epoxide. In cells equipped with 
LTA4 hydrolase, such as neutrophils and monocytes, LTA4 is converted in the 
dihydroxy acid LTB4, which is a powerful chemo-attractant for neutrophils. 
On the other hand, in cells where LTC4 synthase is expressed, such as mast 
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(GSH) forming the first of the cysteinyl-LTs, LTC4. Outside the cells, LTC4 
can be converted by ubiquitous enzymes to form successively LTD4 and LTE4. 
The cysteinyl-LTs C4, D4 and E4 are responsible for contraction of bronchial 
and vascular smooth muscles and of the increased permeability of small blood 
vessels. Moreover, they are able to enhance secretion of mucus in the airway 
and gut and to recruit leukocytes to sites of inflammation. 
LTs are involved in asthmatic and allergic reactions and act to sustain 
inflammatory reactions causing or potentiating airflow obstruction, increasing 
secretion of mucus, mucosal accumulation, broncho-constriction and 
infiltration of inflammatory cells in the airway wall. 
PGs, synthesized as response to inflammatory stimuli, are lipidic compounds 
produced by different cells. For example, whereas mastocytes biosynthesize 
PGD2, macrophages and monocytes produce preferentially PGE2 and PGF2. 
The main PGs involved in inflammation are PGE2, produced by stimulated 
macrophages, and PGI2, also called prostacyclins, produced by vascular 
tissues. Their principal effect is vasodilatation, but they can also increase the 
exudation of fluid and supply leukocytes by increasing flow through vessels 
that are already leaky, without affecting permeability or causing diapedesis. 
PGs contribute to all the four cardinal signs of inflammation listed by 
Cornelius Celsus and previously discussed: rubor, tumor, calor and dolor. 
Overall, the main role of PGs in inflammation is to guarantee an ample supply 
of blood despite local controlling factors.
[24]
 
As shown in Figure 1, a common precursor of PGs and prostacyclins is PGH2. 
In fact, the opportune Tx or PG synthase converts it to Tx or to the other PGs, 
involved in the arachidonic cascade, respectively. Consequently, because of 
the main actors of inflammation are PGE2, drugs able to inhibit their 
production are particularly efficient in the treatment of inflammatory diseases.  
The anti-inflammatory drugs commercially available are classified in steroidal 
(SAIDs) and non-steroidal (NSAIDs) on the basis of their chemical structures 
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and targets. Specifically SAIDs act on PLA2, whereas NSAIDs act as 
inhibitors of the COX enzyme.  
  
1.2. Anti-inflammatory targets 
1.2.1. Phospholipase A2 (PLA2) 
PL is the enzyme hydrolyzing membrane phospholipids into fatty acids and 
other lypophilic substances. On the basis of the catalyzed reactions, PLs are 
classified in four classes: A, B, C and D (Figure 2). Specifically, the class of 
PLA is involved in the cleavage of acyl chains and contains PLA2, that is 
responsible for the releasing of the arachidonic acid, and PLA1, which 
removes the 1-acyl group. On the other hand, PLB, known as 
lypophospholipase, acts on both the acyl chains, while PLC is involved in 
signal transduction because it cleaves phosphate group and releases 
diacylglycerol and a phosphate-containing head group. Finally, PLD cleaves 




















Figure 2. Hydrolisis of phosphatidilinositole by PLs. 
On the basis of this short description, we can easily deduce that the isoform 
involved in inflammation is PLA2. Therefore, it can be considered an 
interesting target for the development of anti-inflammatory drugs as it begins 
the arachidonic acid cascade. Molecules able to act indirectly on PLA2 are 








 They interfere with lipocortin-1 (annexin-1) 
synthesis, which is responsible for the suppression of PLA2 expression.  
A wide range of molecules of natural origin have been discovered to be able to 
irreversibly inhibit this enzyme. Particularly interesting in this field is the 
family of marine sesterterpenes containing a γ-hydroxybutenolide moiety, such 
us manoalide, cacospongionolides and petrosaspongiolides, that have been the 
object of extensive investigations by our research group with the aim of 
identifying the mechanism of interaction at molecular level.
[28]
 
In addition to the production of eicosanoids, PLA2-catalyzed membrane 
phospholipids hydrolysis is also the initiating step in the generation of PAF, a 
potent inflammatory agent. Thus, inhibition of PLA2 activity should be, in 
theory, a really effective anti-inflammatory approach. However, PLA2 have 
been proved to determine the massive suppression of prostanoids and LTs 
production, including those constitutively expressed and involved in crucial 
physiological functions.  
 
1.2.2. Cyclooxygenase (COX) 
COX is the enzyme responsible for the formation of prostanoids, including 
PGs, prostacyclins and Tx. This biosynthesis takes place on the two active 
sites: the cyclooxygenase and the peroxidase. Specifically, the first one is 
responsible for the conversion of arachidonic acid in the hydroperoxy 
endoperoxide PGG2, whereas peroxidase site is involved in the reduction of 
PGG2 to PGH2 (Figure 1).  
Today three different isoforms of COX are known: COX-1, COX-2 and COX-
3, a variant of COX-1. Whereas COX-1 is considered a constitutive enzyme, 
COX-2 is an inducible enzyme, becoming abundant in activated macrophages 
and other cells in the sites of inflammation. COX-1 and COX-2 are 
characterized by 65% aminoacid sequence homology and near-identical 
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catalytic sites. The most significant difference between the two isoenzymes is 
the substitution of Ile at position 523 in COX-1 with Val in COX-2.
[29]
 
The first molecule able to non-selectively inhibit COX is acetylsalicylic acid 
that, in 1899, was marked and commercialized as Aspirin. After about six 
decades new NSADs were employed in treatment of inflammatory diseases 
with aspirin-like actions. It is worth to note that aspirin-like drugs were 
initially developed without a rationale mechanistic support, as their 
mechanism of action was not discovered until 1971. Indeed, they revealed 
hard gastrointestinal and renal side-effects due to the non-selective inhibition 
of all PGE2, including those constitutively expressed and involved in gastric 
mucosa and kidney protection.
[30]
  
The discovery of COX-2 isoform and the elucidation of its 3D structure, in 
1999, allowed the design and synthesis of selective COX-2 inhibitors, the well 
known “coxibs” such as celecoxib and rofecoxib.
6
 At the beginning they were 
considered the solution to all the problems connected with the use of the 
conventional anti-inflammatory drugs, because of the selective suppression of 
prostanoids induced by inflammatory stimuli in the gastro-intestinal mucosa 
and platelets.
[6;29]
 Unfortunately, it was early demonstrated that long term 
treatment with coxibs led to increased risks for heart attack, thrombosis and 
stroke, probably due to an unbalance between anti-thrombotic agents, such as 
prostacyclins, and pro-thrombotic molecules, like Tx.
[8]
 
The failure of this class of anti-inflammatory drove the scientific community 
to search novel and safer anti-inflammatory targets. Indeed, recently, 
researchers focused their attention on a new class of interesting enzymes 
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1.3. Prostaglandin E2 Synthase (PGES) 
PGES is the enzyme involved in the terminal step of the biosynthesis of PGE2 
(Figure 1). Specifically, it is responsible for the isomerization of the COX-
derived peroxide PGH2 in PGE2.
[31]
 Three isoforms of this enzyme have been 
identified and cloned: cytosolic PGES (cPGES),
[32]
 membrane PGES-1 
(mPGES-1) and membrane PGES-2 (mPGES-2).
[33]
 Both cPGES and mPGES-
2 are constitutively expressed in various cells and contribute to the basal PGE2 
synthesis with the difference that while mPGES-2 is functionally coupled with 
the activity of COX-1 and COX-2,
[32;34]
 cPGES is functionally coupled with 
COX-1.
[33]
 On the contrary, mPGES-1 is the predominant isoform involved in 
COX-2-mediated PGE2 production
[35]
 and represents the only isoform mainly 
induced by various inflammatory stimuli.
[36]
 This feature makes mPGES-1 an 
extremely interesting target because its inhibition is connected to the 
suppression of inducible PGE2 responsible for inflammatory pathologies that 
should reduce the typical side effects of the anti-inflammatory drugs 
commercially available. 
 
1.3.1. Microsomal prostaglandin E2 synthase (mPGES-1) 
Human mPGES-1 is a membrane protein of 16 KDa and represents the first 
isoform of PGES identified and cloned by Jakobsson et al. in 1999.
[37]
 It is a 
member of the membrane associated proteins involved in eicosanoid and 
glutathione metabolism (MAPEG) family, which also contains LTC4 synthase, 
5-lipoxygenase-activating protein (FLAP) and three GSH 




mPGES-1 is a homotrimer
[39;40]
 with each monomer consisting of four 
transmembrane helices (TM1-4) and a large cytoplasmatic loop between TM1 
and TM2. The three TM2s of each trimer form an inner core with a funnel-
shaped opening towards the cytoplasmatic side. GSH, bound in a U-shaped 
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conformation, is located at the interface between subunits in the protein trimer 
being exposed to the lipid bilayer.
[40]
 GSH is an essential cofactor for catalytic 
turnover.
[37]
 In fact, it seems that it is responsible for a catalytic mechanism in 
which its thiolic function attacks the peroxide of PGH2.
[41;42]
 Structure 
comparisons between LTC4 synthase and mPGES-1 suggest that mPGES-1 has 
to undergo conformational changes from a closed to an open conformation 






































Figure 3. Molecular mechanisms proposed for GSH-dependent 
 conversion of PGH2 to PGE2. 
Concerning the molecular mechanism of GSH-dependent conversion of PGH2 
to PGE2, two mechanisms have been proposed, both provide a nucleophilic 
attack by the thiolate anion of GSH (GS
-
). Specifically, the first mechanism 
proposed consists in a GSH-assisted hydride shift with the formation of the 
instable intermediate, thiohemiketal. Successively, the nucleophilic thiolate 
anion attacks the peroxide oxygen on C-9 and brings to the adduct between 
GSH (or enzyme cystein thiol) and PGH2. The following enzyme-assisted 
deprotonation of C-9 furnishes PGE2 and thiolate anion GS
-
. Then another GS
-
 
(or enzyme cysteine thiolate) in solution acts as base in the second step (Figure 
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glutathione or enzyme cysteine thiolate removes the proton on C-9 of PGH2 




1.3.2. Pathologies where mPGES-1 is involved 
Recent studies demonstrated that mPGES-1 is over-expressed and plays a 
pivotal role in diseases related to inflammation and tumorigenesis.
[45-47]
 
Nevertheless it is constitutively expressed at low level in few tissues in mice 











 lung, spleen and gastric mucosa
[30]
 where its 
physiological functions are not well understood. 
The over-expression of mPGES-1, along with COX-2, seems to be stimulated 
by several pro-inflammatory stimuli and mediators such us interleukin-1β (IL-
1β), tumor necrosis factor-α (TNF-α) and LPS, in different cells and tissues. In 
addition, in humans, it is up-regulated in arthritic synovial tissues,
[52]
 in the 
cartilage and chondrocytes of osteoarthritic patients
[53-55]
 and in inflamed 
intestinal mucosa of patients with inflammatory bowel diseases.
[56]
 Moreover, 
mPGES-1 seems to be responsible not only for atherosclerotic carotid 
plaques,
[57]
 but it is expressed in Alzheimer disease tissues
[58]
 and heart tissue 
after acute myocardial infarction;
[32]
 it is also abundant in liver tissue from 
patients with hepatitis and muscle biopsies from people with polymyositis or 
dermatomyositis.
[59]
 Closely related to the inflammatory diseases, mPGES-1 is 
recently emerged to be involved in the pathogenesis of different form of 
cancers and in induction of angiogenesis.
[60]
 Specifically, several clinical 





















 Moreover, the elevated levels of mPGES-1 and mPGES-2 
correlate with a worse prognosis in late stages of colorectal cancer,
[71]
 
suggesting that the PGE2 synthase may play a key role in cancer progression. 
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Finally, mPGES-1-derived PGE2, in cooperation with vascular endothelial cell 
growth factor (VEGF), seem to play a critical role in the development of 
inflammatory granulation and angiogenesis. Indeed, mPGES-1 deficiency has 
been well documented to be associated with reduced induction of VEGF in the 
granulation tissue.
[72]
 On the basis of all these considerations mPGES-1 
inhibition could be considered a valid strategy not only for the treatments of 
inflammatory diseases but also in chemotherapeutical field. 
 
1.3.3. mPGES-1 as pharmacological target 
As discussed before, elevated levels of mPGES-1 are often observed in 
connection with COX-2 over-expression.
[35;73]
 Nevertheless, it has recently 
emerged that mPGES-1 can also be functionally activated in the absence of 
induced COX-2 levels,
[74]
 providing evidence that these two enzymes can be 
independently regulated. This could corroborate that mPGES-1 is outlined as a 
promising drug target for inflammatory diseases because its inhibition leads to 
the reduction of inducible PGE2 by mechanisms that circumvent the toxicity 
associated with inhibition of COX-1 and COX-2 activity. Actually, this last 
issue is still debating because in some cell type a redirection of prostanoid 
synthesis to other prostanoid synthases has been observed after mPGES-1 
inhibition.
[30;75-77]
 Hence, the therapeutic efficiency and safety of drugs 
targeting mPGES-1 remains to be further investigated; thus selective mPGES-
1 inhibitors are strongly required to fully clarify some crucial mechanicistic 
details.  
Recently increasing evidences outline the possibility of a dual inhibition of 
mPGES-1 and 5-LO as a more effective approach in inflammatory diseases. 
This strategy rely on the consideration that suppression of both LTs and PGs 
synthetic pathways might be of advantage in terms of effectiveness and relief 
from side effects.
[78]
 In fact, LTs are involved in gastric epithelial injury and 
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cardiovascular side-effects of traditional NSAIDs and coxibs, respectively.
[79]
 
In any case, even this topic, that is whether dual inhibition of mPGES-1 and 5-
LO is of therapeutic value, needs to be further investigated.  
On the basis of these considerations, in the last years the interest for mPGES-1 
as therapeutic target is still increasing. Despite many efforts have been profuse 
in this area, only a few small molecules have been discovered to target this 
enzyme. In theory to affect mPGES-1 levels two different approaches can be 
used: an inhibition of mPGES-1 expression or a selective inhibition of 
mPGES-1 activity. The first strategy consists in the identification of molecules 
potentially able to negatively modulate the expression level of the gene 
responsible for mPGES-1 biosynthesis. The second approach consists in the 
discovery of molecules that could directly and selectively inhibit the activity 
of the enzyme.  
 
1.3.4. mPGES-1 inhibitors 
1.3.4.1. Inhibitors of mPGES-1 expression 
As mentioned before, an interesting approach to affect mPGES-1 activity 
consists in the modulation of the enzyme expression. So far the only molecules 














7 8 9 10
 
Chart 3. Inhibitors of mPGES-1 expression. 
In more details, compound 6 is a γ-hydroxybutenolide-derivative identified by 
our research group, that potently inhibits PGE2 formation (IC50 = 1.8 µM) in 
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LPS-stimulated RAW264.7 cells through a selective inhibition of mPGES-1 




The polyphenolic antioxidant resveratrol 7 (Chart 3) was found to suppress 
cellular PGE2 formation (IC50 = 2.5-30 µM) by modulation of multiple events 
in PGE2 biosynthesis.
[80]
 Indeed, in addition to its anti-oxidative effects and 
ability to inhibit the COX-1 peroxidase reaction (IC50 = 0.1-1 µM),
[81]
 
compound 7 selectively blocks the induction of mPGES-1, without any effect 
on COX-1 or COX-2, in LPS-stimulated rat microglial cells (IC50 = 10-25 
µM).[82] 









 (Chart 3) that combine direct mPGES-1 inhibition 
with repression of mPGES-1 induction. 
 
1.3.4.2. Small molecules as inhibitors of mPGES-1 activity 
The alternative approach to inhibit the activity of mPGES-1 consists in the 
discovery of potential ligands able to directly interact with the enzyme 
blocking its activity. In the last years we assisted to a considerable increase of 
publications and patent applications concerning this field. Based on the data 
reported in literature we can found non selective and selective inhibitors of 
mPGES-1.  
 
1.3.4.2.1. Non-selective inhibitors of mPGES-1 
On the basis of the chemical features, non-selective enzyme inhibitors can be 
divided in two groups. In the first group we found NSAIDs and Coxibs while 
endogenous fatty acids and lipid mediators belong to the second one.  
Among the NSAIDs and Coxibs (Chart4) it is worth to note some COX-2-
selective drugs possessing carboxylic or sulfonylamide groups, such us  
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(IC50 = 75 µM)
[84]
 and NS-398 14 (IC50 = 20 µM),
[74]
 that have been identified 
as mPGES-1 inhibitors in cell-free assays, even if at a concentration 
substantially higher than those needed for COX-2 inhibition. In addition, the 
Coxibs derivative dimethylcelecoxib 9 does not inhibit COX-2,
[86]
 whereas 
inhibits mPGES-1 (IC50 = 16 µM) better than celecoxib 11,
[84]
 probably via an 
allosteric mechanism, as PGE2 formation is only partially inhibited even at 
higher concentration (1 mM). Finally, among the traditional NSAIDs, only the 
active metabolite of the prodrug sulindac, the sulindac sulfide 15 (IC50 = 80 
























Chart 4. Non-selective mPGES-1 inhibitors: NSAIDs and Coxibs. 
Among the unsaturated and non-unsaturated fatty acids the molecules that 
showed the most potent inhibitory activity are arachidonic acid, 
eicosapentaenoic acid and docosahexaenoic acid (IC50 = 0.3 µM, each),
[87]
 
along with palmitic acid (IC50 = 2 µM), 6-heptenoic acid (IC50 = 30 µM) and 
15-deoxy-Δ
12,14-
PGJ2 (IC50 = 0.3 µM).
[87] Finally, 
also LTC4 moderately inhibits 
mPGES-1 (IC50 = 5 µM),
[74]
 probably thanks to a competition with GSH,
[88]
 
necessary for mPGES-1 activity. 
 
1.3.4.2.2. Selective inhibitors of mPGES-1 
On the basis of chemical features, selective mPGES-1 inhibitors can be 
classified in derivatives of MK-886, azaphenathrenone and oxicam (Chart 5). 
MK-886 8 was originally described as potent inhibitor of FLAP (IC50 = 2,5 
µM) and later revealed an interesting inhibitory activity on mPGES-1 (IC50 = 
2,4 µM). Starting from this lead structure, several potential inhibitors of 
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mPGES-1 were developed and some of them revealed IC50 values in the 
nanomolar range (16  IC50 = 7 nM and 17 IC50 = 3 nM).
[89]



































Chart 5. Selective inhibitors of mPGES-1. 
 
Furthermore, the JAK kinase inhibitor azaphenanthrenone 18
[90]
 was 
discovered to be able to inhibit both cell-free mPGES-1 activity (IC50 = 0.14 
µM) and PGE2 formation in IL-1β-stimulated A549 cells (IC50 = 1.6 µM, 50% 
FCS) and was used as new lead compound.
[91]
 Its structural optimization led to 
the discovery of several analogues, whose activity was not particularly 
interesting, and of MF63 19 that revealed a potent inhibitory activity on 
mPGES-1 (IC50 = 1 nM).
[91]
 
Finally, also the oxicam template has emerged as an interesting lead 
compound for the synthesis of potent and selective mPGES-1 inhibitors. 
Specifically, compound 20 showed to selectively inhibit mPGES-1 in 




1.3.4.3. Dual inhibitors of mPGES-1 and 5-LO 
As mentioned before, suppression of both LTs and PGs biosynthetic pathways 
might be more advantageous than single interference with prostaglandins 
formation, in terms of anti-inflammatory effectiveness and of reduced 
incidence of gastrointestinal and cardiovascular side-effects showed by the 
traditional NSAIDs and coxibs, respectively.
[78]
 This assumption paved the 
way for the development of a new class of molecules able to inhibit both 














MK-886 8 and its derivatives seem to interfere with cellular PGE2 biosynthesis 
also through other mechanisms different from a direct inhibition of mPGES-1. 
For example, they were proved to interfere with several members of the 
MAPEG family (FLAP, mPGES-1, and LTC4 synthase)
[95;96]
 that might result 
from a conserved amino acid motif within this family,
[97]
 in the MK-886 
binding pocket of FLAP.
[98]
 Furthermore, licofelone 21, currently undergoing 
phase III trials for osteoarthritis, showed potent anti-inflammatory properties 
in clinical and pre-clinical studies lacking gastrointestinal toxicity.
[99]
 This 








The dual mPGES-1 and 5-LO pirinixin acid derivatives inhibitors were 
synthesized starting from the PPARγ agonist WY-14,643. The structural 
optimization of this lead compound led to the discovery of the potent 
carboxylic acid 22 which represents the most potent dual inhibitor within this 



































Chart 6. Dual inhibitors of mPGES-1 and 5-LO. 
Finally among the acylphloroglucinols noteworthy are myrtucommulone 23 
(mPGES-1: IC50 = 1.0 µM; 5-LO: IC50 ˂ 30µM) from myrtle, hyperforin 24 
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(mPGES-1: IC50 = 1.2 µM; 5-LO: IC50 = 0.09 µM) from St. John‟s wort and 
garcinol 25 (mPGES-1: IC50 = 0.3-1.2 µM; 5-LO: IC50 = 0.1 µM).
[94]
 Their 
activity seems to be connected with the presence of acylphloroglucinol core 26 




1.4. Aim of the project  
On the basis of the considerations that mPGES-1 inhibitors could represent a 
new frontier in the field of anti-inflammatory drugs, the scientific community 
focused the attention on this attractive target with the aim of developing 
molecules able to act either directly on the enzyme or to affect its expression.   
Although some structurally different compounds able to potently inhibit 
mPGES-1 have been developed, the discovery of new and more effective 
mPGES-1 inhibitors are strongly required in order to confirm the real 
efficiency and safety of these molecules in humans. 
On the basis of these considerations, the first aim of this project was directed 
to the identification of new small molecules modeled on the natural marine 
compound PM 5, able to negatively modulate the expression of mPGES-1. In 
more details, starting from a previous project developed by our research group 
that provided the identification of compound 6 as a very interesting mPGES-1 
negative modulator, we tried to optimize its activity performing some well 
reasoned chemical modification on the lead scaffold. As second, we focused 
our attention on the development of new synthetic simplified derivatives of 
PM 5 in order to amplify the chemical diversity of the parent γ-
hydroxybutenolide scaffold, in the attempt to identify new compounds able to 
inhibit the expression of the enzyme. As last step of this project, we 
considered the possibility to discover potential binders of the target enzyme 
able to selectively block its activity. In this frame we took advantages of 
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triazole nucleus that, on the basis of a preliminary virtual screening showed a 
significant binding affinity for mPGES-1 enzyme. 
 
1.5. Methodologies employed 
Before starting the discussion concerning the results obtained, in our opinion it 
is appropriate to do first a brief introduction on the methodologies utilized to 
realize the project. Actually, to synthesize the three above mentioned small 
libraries, we took advantages on some advanced strategy of organic synthesis 
like Suzuki coupling, Huisgen‟s 1,3-dipolar cycloaddition and photooxydation 
reactions that have been properly optimized to provide the desired compounds 
in good yields. To gain safe predictions of the effectiveness of our molecules, 
we exploited molecular docking calculation and a de novo design approach as 
Ludi. Finally, to speed up the reactions and increase products yield, we 
employed microwaves technology. 
 
1.5.1. Molecular docking 
Molecular docking is the computational process of searching for a ligand that 
is able to fit both geometrically and energetically the binding site of a target 
protein. It is frequently used to predict the affinity and activity of potential 
binders for a protein; hence it plays a crucial role in rational drug design. The 
recent improvement of molecular docking finds its driving force not only in 
the drastic growth of computer availability and power, that characterize the 




The application of computational methods to study the formation of 
intermolecular complexes has been the subject of intensive research during the 
last years. It is widely accepted that drug activity is the result of the molecular 
binding of a small molecule, called ligand, to the pocket of another, generally 
a protein, known as receptor. In their binding conformations, the ligand and 
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receptor exhibit geometric and chemical complementarities, both of which are 
essential for successful drug activity.  
Since the rapid generation of lead compounds represents the main requirement 
in the development of bioactive compounds, accurate automated procedures 
would be extremely useful in the drug discovery field. In this frame, ligand–
protein docking is a powerful method able to predict the predominant binding 
modes between a ligand and the 3D structure of a given protein and can help 
synthetists to focus their efforts toward the most promising compounds. 
Hence, molecular docking can be used to perform a preliminary virtual 
screening on large libraries of compounds, ranking the results and proposing a 
possible binding mode between the ligand and the own target. This can be 
helpful also in structural optimization process to provide preliminary guiding 
lines in structure–activity studies. 
Among the softwares available for docking calculation, one of the most used is 
AutoDock. This program was originally developed in 1990 by D. S. 
Goodsell
[108]
 to perform automated docking of ligands on their 
macromolecular target. Since then its application in medicinal chemistry 
became ever increasing. 
 
1.5.2. De novo design 
A different approach to rationally individuate potential ligands for a defined 
target is the relatively new software Ludi, introduced in 1990 by Accelrys Inc. 
in collaboration with Prof. H. J. Böhm. It works positioning small molecules 
into clefts of protein structures, commonly the active site of an enzyme, in 
such a way that hydrogen bonds can be formed with the enzyme and 
hydrophobic pockets are filled with hydrophobic groups. The program acts in 
three steps (Figure 4). As first it calculates interaction sites, which are discrete 
positions in space suitable to form hydrogen bonds or to fill a hydrophobic 
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contacts generated by a search through the Cambridge Structural Database. 
The second step consists in the fit of molecular fragments onto the interaction 
sites. The final step is represented by the connection of some or all of the fitted 
fragments to a single molecule using bridge fragments.
[109]
 To guarantee the 
synthetic accessibility of the selected molecules, Ludi is equipped with 
Ludi/CAP, a library of compounds based on two databases: Chemical 
Available for Purchase (CAP), which is a database of the commercially 
available compounds and CAPScreening, a database of molecules available in 
specific libraries.  
Obviously the generated compounds do not have the same potency but 
everyone has an own score. On the basis of the score value it is extremely 
useful to screen the results and identify the most promising compounds that 
will be synthesized. 
 
Figure 4. Scheme of software Ludi operations. 
Ludi has been largely used in drug discovery and in particular I took 
advantages of its use to generate a focused collection of PM 5 simplified 
analogues in order both to amplify the chemical diversity and to simplify the 
synthetic procedures. 
 
1.5.3. Suzuki cross-coupling reaction 
The Suzuki cross coupling reaction was first reported by A. Suzuki and his 
group in 1979.
[110]
 It is a versatile methodology to generate carbon-carbon 
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bonds and it is widely used to synthesize poly-olefins, styrenes and substituted 
biphenyls. It is extremely useful in preparative organic chemistry not only for 
the synthesis of natural or synthetic products, but also to prepare new 
materials.  
Basically Suzuki coupling takes place among an aryl- or vinyl-boronic acid 
acting as nucleophile with an aryl-, vinyl- or an alkyl-halide and is catalyzed 
by Ni(0) and Pd(0). As reported in Figure 5, by analogy to the other organo-
catalytic cross coupling reactions, the mechanism of the catalytic cycle of 
Suzuki coupling reaction involves three basic steps: 1) oxidative addition, 2) 






















Figure 5. Catalytic cycle of Pd(0) in Suzuki cross-coupling reaction. 
The reaction is initiated by oxidative addition of the appropriate halides (1-
alkenyl, 1-alkynyl, allyl, benzyl or aryl halides) to a Pd(0) species affording a 
stable trans-δ-palladium(0) complex (a). The reaction proceeds with complete 
retention of configuration for alkenyl halides and with inversion for allylic and 
benzylic halides. Oxidative addition is often the rate-determining step in a 
catalytic cycle; hence it is fundamental that the substrate is sufficiently 
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substrate decreases in the order of I > OTf > Br >> C1. Moreover, the aryl and 
1-alkenyl halides, activated by the proximity of electron-withdrawing groups, 
are more reactive to the oxidative addition than those with donating groups. 
Afterwards, halogen linked on a organo-palladium (II) halide is readily 
displaced by the base anion to provide the reactive R1-Pd-OH complex (b).
[112]
 
Because of the low nucleophilicity of organic group on boron atom, the cross 
coupling reaction requires the presence of a suitable base that coordinates the 
organic group on boron atom and enhances its nucleophilicity. Indeed the 
quaternization of the boron with negatively charged base makes easier the 
transmetallation of activated organic group to the Pd(II) complex with the 
consequent formation of trans R1-Pd-R2 (trans-c).
[113]
 
Reductive elimination of organic partners from (b) reproduces the 
palladium(0) complex and affords the desired cross coupling product. The 
reaction takes place directly from cis-c intermediate, obtained from the 
isomerization to the corresponding trans-c complex. The order of reactivity is 
diaryl->(alky1)aryl->dipropyl->diethyl->dimethylpalladium(II), suggesting 
participation of the π-orbital of aryl group during the bond formation. 
As the reaction is greatly affected by the experimental conditions, its success 
depends on the right choice of catalyst, base and solvents. In more details, a 
very wide range of palladium(0) catalysts or precursors can be used for cross-
coupling reaction. Pd(PPh3)4 is the most commonly used, but PdCl2(PPh3)2 
and Pd(OAc)2 plus PPh3 or other phosphine ligands are also efficient since 
they are stable to air and readily reduced to the active Pd(0) complexes with 
organometallics or phosphines used for the cross-coupling. Palladium 
complexes that contain fewer than four phosphine ligands or bulky phosphines 
such as tris(2,4,6-trimethoxyphenyl)phosphine are, in general, highly reactive 
for the oxidative addition because of the ready formation of coordinate 
unsaturated palladium species. Among the available bases, particularly 
efficient are sodium or potassium carbonate, phosphate, hydroxide, fluoride 
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and alkoxide. The bases can be used as aqueous solution, or as suspension in 




1.5.4. 1,3-dipolar cycloaddition among terminal alkyne and azide 
Huisgen‟s 1,3-dipolar cycloaddition
[114]
 among terminal alkynes and azide, are 
exergonic fusion processes that join two unsaturated reactants and provide fast 
access to an enormous variety of five-membered hetero-cycles. These process 
belong to click chemistry reactions which represent a revolution in the organic 
synthesis in response to the requests of drug discovery. Actually a click 
reaction is a process furnishing consistently high yields of products in brief 
time and in a few steps, starting from a wide variety of reactants. Moreover, it 
is easy to perform, insensitive to oxygen or water and it uses only readily 
available reagents, generally down market. Finally, work-up of the reactions 
and isolation of the products are simple and furnish pure products that do not 
need of any further chromatographic purification. Concerning lead discovery, 
this strategy gives the possibility to rapidly explore the chemical universe, 
whereas for lead optimization, it enables rapid structure-activity-relationship 
(SAR) profiling, through generation of libraries of analogues. In summary, 
click chemistry has proven to be a powerful tool in biomedical research. 
Obviously, click chemistry does not replace existing methods for drug 
discovery, but rather, it completes and extends them offering possibility to 
simplify the synthetic protocol and to provide the means for faster lead 
discovery and optimization. Indeed, it works well in conjunction with structure 
based design and combinatorial chemistry techniques and, through the choice 
of appropriate building blocks, can provide derivatives or mimics of 
„traditional‟ pharmacophores, drugs and natural products.
[115]
 
The Huisgen‟s 1,3-dipolar cycloaddition between terminal alkyne and azide 
represents the first example of a click reaction.
[114]
 At the beginning, different 
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of all, differently from the most energetic species known, azides and alkynes 
are among the least reactive functional groups in organic chemistry. This 
stability is responsible for the slow nature of the cycloaddition reaction and the 
inertness of these functional groups towards biological molecules and towards 
the reaction conditions inside living systems. Moreover there was the problem 
concerning the regioselectivity: alkynes and azides react to furnish a mixture 
of 1,4 and 1,5 triazoles. The discovery of the possibility to accelerate the 
azide–alkyne coupling under Cu(I) catalysis
[116;117]
 and the beneficial effects of 
water, connected with the complete and selectivity conversion to the 1,4-
disubstituted 1,2,3-triazole
[116]
 gave us the possibility to invest this reaction of 
the title of „a perfect‟ reaction. Given this new process and the ready 
availability of the starting materials, highly diverse, large libraries become 
available quickly. Moreover, there are no protecting groups and purification is 
unnecessary. In addition, this process is really interesting in drug discovery, 
not only because of its reliability as a linking reaction, but also for the 
favorable physicochemical properties of triazoles obtained. Indeed, it works as 
rigid linking units that places the carbon atoms, attached to the 1,4-positions of 
the 1,2,3-triazole ring, at a distance of 5.0 Å, versus 3.8 Å of C-α distance in 
amides. Nevertheless, differently from amides, triazoles cannot be cleaved 
hydrolytically or otherwise and unlike benzenoids and related aromatic 
heterocycles, they are almost impossible to oxidize or reduce. Finally, they 
possess a large dipole moment and nitrogen atoms able to function as weak 
hydrogen bond acceptors.  
Concerning with the mechanistic details of reaction, it has been proposed that 
the catalytic cycle begins with the formation of the Cu(I) acetylide (I) which 
reacts with the azide to give the six membered Cu-containing intermediate 
(III). Then, this last arranges to a thermally and hydrolytically stable triazole 
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Triazole ring has already been employed to identify new lead compounds able 
to act on different targets. As supposed, biological studies showed that this 
scaffold is really interesting and could be employed to develop molecules 
useful for the treatment of different pathologies. Indeed, it has recently 
emerged that molecules with the triazole scaffold are active not only for the 









 but also as inhibitors of mPGES-1 enzyme, as 






































 Figure 6. Catalytic cycle of Cu(I) in 1,3-dipolar cycloaddition.  
 
1.5.5. Photooxydation 
Photooxydation is a reaction in which the substrate gives an initial oxygenated 
adduct that consists of a combination among a substrate and oxygen in absence 
or in presence of a sensitizer absorbing a fundamental component for the 
reaction, light. This kind of reaction is able to furnish a considerable number 
of interesting intermediates. Indeed, the photooxygenation of heterocycles 
leads to a variety of products and serves as an important tool in the synthesis 
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Before starting the description of the photooxydation mechanism, it could be 
useful to briefly explain the proprieties of oxygen in the singlet state and how 
it interferes with organic molecules. 
 
   
Figure 7. Electronic configuration of oxygen. 
Singlet oxygen (
1
O2) is the common name of metastable state of molecular 
oxygen (O2) with energy higher than fundamental state, known as triplet. In 





) has two unpaired electrons localized in the two HOMO orbitals. 
The arrangement of the electronic spin in these two degenerate orbitals 
generates two possible excited states (Figure 7). The first one (singlet, 
1
g), 23 
Kcal higher than the fundamental state, has two paired electrons in the same 





two electrons with opposite spin, coupled, in two different orbitals. On the 
basis of these considerations, as there are no unpaired electrons in both the 
electronic excited states, none of the excited states of the oxygen acts as 
radical but they just exploit the oxidant potential of oxygen. 
But how can we create the singlet oxygen? It is necessary the presence of the 
photosensitiser, a gated light-absorbing substance able to transfer the absorbed 
energy to the oxygen that in this way became excited. Specifically, an 
electromagnetic irradiation excites the photosensitiser to the singlet state 
 
Electronic configuration of O2
in the fundamental state
HOMO expansion: 
configuration of the excited states
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(Figure 8a). At this point, the absorbed energy may be released through two 
different processes: the unexcited dye is restored by emission of a photon as 
fluorescence (Figure 8b) or the electronic system of the photosensitiser 
changes in favor of the triplet state (Figure 8c). 
S + hn 1S Excitation of photosensitiser to singlet state
1S FluorescenceS + hF
1S





Figure 8. Mechanism of generation of 
1
O2 by photosensitiser (S). 
At this point, the role of the photosensitiser is fundamental to determine the 
type of mechanism of photooxygenation (Figure 9). According to Gollnick 
classification,
[123]
 in the Type I the substrate is activated by the sensitizer 
triplet. This last can abstract a hydrogen from a substrate leading to the radical 
R
• 
which then reacts with the ground state oxygen molecule to furnish RO2
•
. 
On the other hand, the energy of the triplet sensitizer can be transferred to the 
ground state oxygen molecule to produce singlet oxygen 
1
O2 which, after 
reaction with R, gives RO2 (reaction of Type II).
[124]
 It is also possible that an 
electron transfer occurs between the excited sensitizer and the substrate with 
formation of a radical cation R
•+
 that can react with 
3
O2 or superoxide anion 
O2
•-
 to furnish RO2
•+ 
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The diverse ways of oxygenation often lead to the same products or may be in 
competition. However a suitable choice of the reaction conditions may address 
the reaction to one type. Hence, for example, halogenated or deuterated 
solvents, low temperatures, continuous flow of oxygen, halogen lamps and 
dyes may favour reactions of Type II. UV light, high energy sensitizers (9,10-
dicyanoanthracene, ketones), polar solvents, oxygen saturated solutions may 





































Figure 10. Derivatives of furan obtained through photooxydation.  
The oxygenation of Type II by singlet oxygen is largely used, whenever 
possible, because of the high selectivity of this species and the mild reaction 
conditions. Indeed, the use of halogen lamps prevents the possibility of the 
decomposition of the peroxidic or hydroperoxidic products which may occur 
with UV lamps. Moreover, due to the high number of the dye-sensitizers 
available, such as rose bengal and blu methylene, the reaction can be carried 
out in a variety of organic solvents, from apolar to polar, including water. 
Specifically, the reactions of Type II, involving excited state (
1
Δg), is 
employed above all in the Schenck‟s and Dies-Alder reactions and has been 
applied to the most studied heterocycles as furans, thiophenes, pyrroles, 
oxazoles, imidazoles, indoles and nitrogen-containing six-membered systems. 
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One of the most useful eterocycle for the synthesis of natural derivatives is 
furan. Indeed, it is known to provide a lot of products including 1,3-
diepoxides, epoxy lactones and hydroxybutenolides (Figure 10). Some of these 
products are formed by thermal decomposition of the unstable endoperoxides. 
For example, the formation of a 3-alkyl-4-hydroxybutenolide requires the 
regiospecific removal of the hydrogen at C-1 position on the endoperoxide that 
can be accomplished by treatment of the endoperoxide with a hindered base at 
low temperature in order to favour base-catalyzed decomposition rather than 



















Figure 11. Regioselective photooxydation of furan. 
This reaction has been widely studied by our research group. In the course of 
our investigations, we observed the formation of a complex mixture of by-
products in absence of relatively strong bases. On the contrary, at -78°C in 
dichloromethane (DCM), strong and particularly bulky bases, especially 
phosphazene, lead to the preferential formation of precursor 3-
bromobutenolides (ratio 8:2) whereas the bulky and strong base 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), able to remove the most acid Hb, 
furnishes the only 4-bromobutenolide (Figure 11).
[125]
 
Photooxydation of furan in presence of singlet oxygen probably represents the 
most important reaction of this group. Indeed, it is largely employed to 
synthesize the γ-hydroxybutenolide ring that characterizes several natural 
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1.5.6. CEM discover 
Microwaves represent today a valid methodology to speed up a lot of the 
reactions widely used. Indeed, microwave-assisted organic synthesis is 
characterized by the spectacular accelerations produced in a lot of reactions as 
a consequence of the heating rate, which cannot be reproduced by classical 
heating. Thanks to this peculiarity, even reactions that do not occur by 
conventional heating can be performed using microwaves. This effect is 
exploited in a lot of fields, such as in the preparation of isotopically labelled 
drugs that have a short half-life,
[126]
 high throughput chemistry like 
combinatorial chemistry and parallel synthesis
[127]
 and catalysis where, the 
short reaction times, preserve the catalyst from decomposition and increase the 
catalyst efficiency.
[128]
 In a few words, higher yields, milder reaction 
conditions and shorter reaction times that characterize microwaves synthesis 
give organic chemists more time to expand their scientific creativity, test new 
theories and develop new processes.  
The development of microwaves technology was stimulated by World War II, 
when the magnetron was designed to generate fixed microwaves frequency for 
radar devices. Further investigation showed that microwaves could increase 
the internal temperature of foods much more than a conventional oven. This 
discovery led to the introduction of the first commercial microwaves oven for 
home use in 1954. Afterwards, in 1980s microwaves irradiation was 
investigated also in organic chemistry, but the common oven appeared not 
appropriate for the laboratory usage. Indeed, acids and solvents corroded the 
interior, there were no safety controls and temperature or pressure monitoring 
and the cavities were not able to sustain possible explosions. Hence, later 
microwave ovens specific for laboratories were designed and now multi-mode 
systems, featuring corrosion-resistant stainless steel cavities with reinforced 
doors, temperatures and pressures monitoring and automatic safety control, are 
commercially available.  
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But what are microwaves? A microwave is an electromagnetic radiation with 
frequencies ranging from 300 to about 300.000 MHz. In microwaves 
irradiation the transmission and absorption of energy is different from 
conventional thermal heating since microwaves transfer energy directly to the 
reactive species. But the innovation of microwave technology concerns with 
the kind of energy involved. Indeed, energy in microwaves photons is 0.037 
Kcal/mol, really low relative to the energy required to cleave molecular bonds 
(80-120 Kcal/mole); thus microwaves will not affect the structure of organic 
molecules and the effect of microwaves absorption is purely kinetic. In this 
way, while traditional heating needs hours and brings to a lot of by-products, 
microwaves technologies allow a rapid rise in temperature and furnish quite 
pure products. One of the most important aspects of the microwaves is the rate 
at which it heats. Microwaves transfer energy at 10
-9
 seconds while the kinetic 
molecular relaxation from this energy is about 10
-5
 seconds. This means that 
energy transfers faster than the molecules can relax. As a consequence, 
temperature instantaneously increases together with collisions which are 
responsible for reduction of reaction time and by-products. What is important 
is that microwaves interact directly with the object being heated exploiting the 
ability of some compounds (liquids or solids) to transform electromagnetic 
energy into heat. Two are the fundamental mechanisms for transferring energy 
from microwaves to the substance being heated: dipole rotation and ionic 
condition. Specifically, dipole rotation is an interaction by which polar 
molecules try to align themselves with the rapidly changing electric fields of 
the microwaves. The rotational motion of the molecules trying to orient 
themselves with the field results in a transfer of energy. On the other hand, 
ionic conduction depends on free ions or ionic species present in the 
substances being heated. Indeed, as the molecules try to orient themselves to 
the rapidly changing field, the electric field generates ionic motion which is 
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considerations, it is clear that that microwave irradiation is a selective way of 
heating that generates rapid intense heating of polar substances whereas apolar 
substances do not absorb the radiation and are not heated. These thermal 
effects are a consequence of the inverted heat transfer, the non-homogeneity of 
the microwave field within the sample (hot spots) and the selective absorption 
of the radiation by polar compounds even in presence of apolar ones. In this 
way, it is possible to modify the selectivity of a given reaction or to avoid 
decomposition of thermally unstable compounds. These effects can be 
efficiently used to improve processes, modify selectivity or even to perform 
reactions that do not occur under classical conditions.  
Today microwaves are employed to speed up a plethora of different reactions 
and to increase the yields of the target product. For example, the use of 
microwaves technology have been described in medicinal and combinatorial 
chemistry,
[127]
 in cycloaddition reactions
[129]












 Furthermore microwaves reactions use less solvent 
than conventional reaction and, in some cases, offers the possibility to conduct 
solvent-free reactions. This is an interesting feature that allows the use of 
microwaves technology also in the green chemistry
[134]
 accelerating reactions 
and avoiding decomposition of thermally unstable compounds.
[135]
 
Among the instruments available, in our synthesis we took advantages on 
Discover® system, commercialized in the last years by CEM Corporation. 
This instrument is cheap and easy to use, so that it is employed in academies 
and industries. It is characterized by a single-mode cavity where homogeneous 
and intense reproducible energy is produced. In addition, it offers the 
possibility to conduct reaction both in normal glassware (until 125 mL) at 
atmospheric pressure and in pressurized conditions using specific vials (until 
80 mL) resistant at 300 psi. 
 
 
____________________________________________ Risults and Discussion 
 



























Risults and Discussion_____________________________________________ 
































____________________________________________ Risults and Discussion 
 











Structural Optimization Process of Compound 6, 











De Simone, R.; Andres, R. M.; Aquino, M.; Bruno, I.; Guerrero, M. D.; Terencio, M. 
C.; Paya, M.; Riccio, R. Toward the discovery of new agents able to inhibit the 
expression of microsomal prostaglandin E2 synthase-1 enzyme as promising tools in 
drug development. Chem Biol Drug Des 2010, 76, 17-24. 
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In order to identify small molecules able to inhibit the expression of mPGES-
1, as first step of this project, we decided to focus our attention on compound 
6, which has been proved to be a potent and selective modulator of mPGES-1 
expression.
[21;22]
 This compound is a simplified derivative of PM 5 (Chart 2), a 
natural marine product able to potently inhibit the human synovial PLA2 type 
IIA, the enzyme responsible for triggering the arachidonic acid cascade.
[14]
 
This interesting hit has been synthesized in the frame of our previous project 
involved in the generation of PM-derivatives as potential inhibitors of PLA2; 
unfortunately the new molecules synthesized by our research group did not 
show a relevant activity toward this target, but an in-depth pharmacological 
study allowed us to identify compound 6 as a very promising negative 
modulator of mPGES-1 expression (IC50 = 1.80 µM). This result can be 
considered of great interest in consideration that so far only few molecules are 
known to be endowed with this activity.
[82]
 
On the basis of these premises, in order to improve the pharmacological 
activity of this γ-hydroxybutenolide derivative, we decided to rely on some 
well-reasoned structural changes of the basic molecule (Chart 7). For this 
purpose, we decided to explore the structure-activity profile of a collection of 
analogues closely related with compound 6. In more details, considering that 
this last consists of a 3-bromo-4-substituted hydroxybutenolide, as first we 
decided to replace the benzothiophene appendage with bioisosteric moieties, 
such as indole and benzofurane units (27a and 27b); as result, we observed a 
clear loss of activity, especially for benzofurane derivative (Table 1). 
Afterwards, we decided to synthesize compounds 27c-d, bearing on C-4 
position of the 3-bromo γ-hydroxybutenolide scaffold an appendage that could 
mimic the same structural moiety present in resveratrol 7, which has recently 
emerged as a potent modulator of mPGES-1 expression.
[82]
 Unfortunately, 
none of these last molecules showed any increase of the activity with respect 
to the lead compound 6. Hence, we decided to investigate the role played by 
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the bromine atom. For this purpose we examined the effects of two arrays of 
regioisomeric debrominated γ-hydroxybutenolides 28e-i and 29e-i 
respectively, previously synthesized by us, in the frame of a project focused on 
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Chart 7. Collection of compound 6-derivatives. 
In the case of 28e, the debrominated 6, we observed a moderate increase of the 
activity (IC50 = 1.25 µM). On the contrary, the other 4-substituted butenolides 
28f-i, except 28g, were found completely inactive. On the basis of these 
results, we can conclude that the elimination of bromine atom from the C-3 
position of the lead compound 6 represents the only structural change proved 
to be effective for the activity. In line with these findings, the other array of 
regioisomeric compounds 29e-i, all presenting substitutions on C-3 position of 
the scaffold, did not give satisfactory results. 
Finally, to verify if the masked aldehyde was crucial for the activity, as it was 
proved to be for the inhibition mechanism of the other known natural 
butenolides,
[28;136;137]
 we decided to perform on the most active derivative so 
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far obtained, compound 28e, a protection of OH either with acetyl 30 or 
tetrahydropyran (THP) group 31e. Compounds 30 and 31e at last displayed a 
higher potency in inhibiting the expression of mPGES-1 (IC50 = 0.79 µM and 
IC50 = 0.85 µM respectively), in comparison with the reference compound 6. 
This can be considered a really interesting result in view of discovery of new 
active molecules able to negatively affect mPGES-1 expression which can 
provide new tools for further mechanicistic investigation.   
 
2.1. Chemistry 
Concerning with the synthesis of this new series of molecules, the crucial step 
that allowed us to obtain compounds 27a-d was a Suzuki coupling between 
the metoxy-ethoxy-methyl (MEM)-protected-mucobromic acid 34 and the 
appropriate boronic acid a-d (Scheme 1).  
The first problem we had to solve, in order to apply this procedure, was the 
instability of the butenolide ring, observed also by Zhang,
[138]
 in the basic 
condition required by Suzuki coupling. The decomposition of the scaffold is 
connected with the equilibrium that characterizes the butenolide moiety in 
solution: with the increase of pH the opening of the five-membered ring with 

















Figure 12. Decomposition of butenolide ring with pH increasing. 
In more details, as depicted in Figure 12, in acid solution the cyclic structure is 
predominant, nevertheless with the pH increasing, the open form becomes 
more stable and, turning into its stereoisomer, it definitely evolves in by-
products. This process can be avoided blocking the hemiacetal function. The 
choice of the protecting group has to be accurately done as this must be stable 
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in the alkaline conditions, required by Suzuki coupling, and easy to remove at 
the end of the reaction without affecting the other groups present on the main 
scaffold. Among the large number of known OH-protective groups, our choice 
fell on MEM for several considerations:
[140]
 it is sufficiently stable in non-
extreme alkaline solution and easy to remove in acid conditions. As next step 
we connected the MEM-protected-γ-hydroxybutenolide scaffold 34 with the 
suitable boronic acids a-d,
[140]
 using the Suzuki coupling reaction,
[110]
 
previously optimized by us.
[141]
 This reaction was performed through the 
microwaves heating strategy,
[142]
 which allowed us to obtain the desired 
compounds 35a-d in good yields, with low formation of by-products, mainly 
consisting of bis-coupling and homo-coupling adducts. Finally, the cleavage of 
MEM-protecting group with a solution of trifluoroacetic acid (TFA) 95%, 

























aReagents and conditions: (i) MEM-Cl, DIPEA, CH2Cl2, r.t., 4h; (ii) Pd(dppf)Cl2, TBAB, CsF, THF/H2O 
1:1, MW, 120°C, 3-6 min; (iii) TFA (95%), TIS (2.5%), H2O (2.5%), r.t., 2h. 
Scheme 1. Synthetic protocol to generate derivatives 27a-d. 
The two regioisomeric debrominate arrays 28e-i and 29e-i were obtained using 
the optimized protocol of photooxidation reaction performed on 3-bromofuran 
36 in presence of a suitable base.
[125]
 Specifically, to obtain the 3-
bromobutenolide derivatives 28e-i we performed the oxidation in presence of 
phosphazene that led to the preferential formation of 3-bromobutenolide (ratio 
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8:2). On the contrary, to obtain the regioisomer 4-bromobutenolide derivatives 













































Figure 13. Protective reaction of 3- and 4-bromo-5-hydroxy-5H-furan-2-one with 
methoxy-ethoxy-methyl-ether (MEM).  
Also in this case, to connect the aromatic appendages on the scaffold, we 
decided to perform a Suzuki coupling. As previously described for the 
brominated derivatives, even in this case the γ-hydroxybutenolide ring needed 
to be protected to avoid its decomposition in the basic conditions necessary for 
the Suzuki coupling. In more details, to protect the OH-emiacetalic, differently 
from the bromide-derivatives, we selected THP. This choice was in 
accordance with our previous findings and could avoid the risk of obtaining 
mainly MEM-ester byproducts instead of the desired MEM-protected 
monobrominated γ-hydroxybutenolides (Figure 13).
[125]
 
Afterwards, a Suzuki coupling between the THP-γ-hydroxybutenolides 38 and 
40 and the appropriate boronic acids e-i afforded the desired products 31e-i 
and 32e-i whereas their deprotection with a solution of TFA/TIS/H2O 
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95:2.5:2.5 gave us the analogues 28e-i and 29e-i. Finally, the acetylation of 






















































aReagents and conditions: (i) P1-octyl-phosphazene, rose bengal, 
1O2, CH2Cl2, -78°C. (ii) DBU, rose 
bengal, 1O2, CH2Cl2, -78°C. (iii) p-tolensulfonic acid, DHP, CH2Cl2, r.t., 4h; (iv) Pd(dppf)Cl2, TBAB, 
CsF, THF/H2O 1:1, MW, 120°C, 3-6 min; (v) TFA (95%), TIS (2.5%), H2O (2.5%), rt, 2h; (vi) 
(CH3CO)2O, DIPEA, DMF, r.t., 2h. 
Scheme 2. Synthetic protocol to generate derivatives  
28e-i, 29e-i, 30, 31e and 32e. 
Concerning with the protocol of Suzuki coupling we took advantages of the 
procedure previously optimized that suggested the use of Pd(dppf)Cl2 as best 
catalyst. Indeed, Pd(II)-complex is considered a suitable precursor of Pd(0) as 
it is stable in presence of air and can be easily reduced in situ by the 
organometals and phosphine used for the cross coupling. Also crucial is the 
choice of the base because of the high instability of butenolide ring in 
extremely alkaline solutions.
[138]
 In this frame the best results were obtained 
using CsF. Finally, concerning the solvents our choice fell on the mixture 
water/tetrahydrofuran (H2O/THF) 1:1 because THF is partially mixable with 
water and is very useful in reactions among reactants with different polarity.   
 
2.2. Bioactivity 
In collaboration with Professor Miguel Paya of the University of Valencia 
(Spain), we evaluated the inhibitory activity of our compounds on mPGES-1 
expression. For this purpose, their effect on PGE2 production on mouse 
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macrophage cell line RAW264.7 stimulated with LPS was preliminary 










27a 81.6 ± 4.7** 4.20 < 5.0 
27b 46.7 ± 6.1** n.d. < 5.0 
27c 45.1 ± 9.7** n.d. < 5.0 
27d 46.5 ± 11.1** n.d. < 5.0 
31e 100.0 ± 0.0** 0.85 28.9 ± 3.0** 
32e 85.1 ± 3.5** 3.40 < 5.0 
28e 87.1 ± 3.9** 1.25 < 5.0 
28f < 20.0 n.d. < 5.0 
28g 76.0 ± 5.7** 3.17 < 5.0 
28h < 20.0 n.d. < 5.0 
28i < 20.0 n.d. < 5.0 
29e 65.9 ± 8.1** 4.46 < 5.0 
29f < 20.0 n.d. < 5.0 
29g n.d. n.d. 89.9 ± 0.2** 
29h < 20.0 n.d. < 5.0 
29i < 20.0 n.d. < 5.0 
30 100.0 ± 0.0** 0.79 < 5.0 
6 72.2 ± 5.7** 1.80 < 5.0 
Results show means ± S.E.M (n=6). Statistical significances: ** p<0.01, with respect to the LPS-
stimulated control group. PGE2 (non-stimulated cells = 0.6 ± 0.2 ng/mL; LPS-stimulated cells = 16.0 ± 
1.6 ng/mL). n.d.= not determined. 
Table 1.  Inhibitory activity and cytotoxic effect of the γ-hydroxybutenolide 
derivatives 27a-d, 28e-i, 29e-i 30, 31e and 32e at 10 µM on the production of PGE2 
in LPS-stimulated RAW 264.7 cells. 
Specifically, after 18 h stimulation, compounds 6, 27a, 31e, 32e, 28e, 29e, and 
30 were able to inhibit PGE2 production with a percentage of inhibition higher 
than 50% at 10 µM, showing IC50 values in the micromolar range. In more 
details, only compounds 30, 31e, and 28e exerted an inhibitory potency higher 
than the leader compound 6. This profile is especially relevant for compounds 
30 and 31e, the two protected derivatives of the debrominated 6. On the other 
hand, all the derivatives except 28g, which was discarded, were devoid of 
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significant cytotoxic effects on RAW264.7 at concentrations higher than 10 
µM, as assessed by the mitochondrial-dependent reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan 
(Table 1). The only exception was compound 31e that showed a slight 
cytotoxic effect which disappeared at lower concentrations. 
 
Figure 14. Effect of derivatives 6, 28e, 30, 31e on mPGES-1 and COX-2 expression 
in LPS-stimulated RAW 264.7 cells. The Figure is representative of two similar 
experiments. B: normal cells. C: LPS-stimulated cells. Dx. dexamethasone. 
 
Finally, to confirm that analogues 30, 31e, 28e and the leader compound 6 
were able to inhibit selectively the mPGES-1 enzyme expression without any 
effect on COX-2, a western blot analysis for mPGES-1 and COX-2 proteins 
using 18 h LPS-stimulated RAW 264.7 cells was performed (Figure 14). The 
results clearly showed that the test compounds inhibit selectively mPGES-1 
expression, without any effect on COX-2, whereas dexamethasone, the 
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The intriguing biological results shown by synthetic analogues of the natural 
compound PM 5,
[21;22;141;143]
 encouraged us to continue our studies on this 
promising marine metabolite. Specifically, in this project as second step we 
decided to undertake the synthesis of a new generation of PM-derivatives 
bearing, on the γ-hydroxybutenolide ring, various molecular decorations in 
order to amplify the chemical space under investigation useful for the 
discovery of new agents with higher potency (Chart 8). Also in this case we 






































































42b 42c42a 42e42d  
Chart 8. Collection of new PM-derivatives. 
As described in Chapter 1, Ludi is a computational method which has been 
proven to be fairly predictive of the affinity properties of potential ligands. It 
was set in order to construct new promising binders for PLA2, starting from 
PM 5 and replacing the sesterterpene moiety of the natural product, with 
suitable molecular fragments. Four classes of PM-analogues have been 
selected by the software; three of them have already been synthesized in our 
research group. Biological tests performed on these collections allowed us to 
individuate weak inhibitors of PLA2 and compounds 6 as potent negative 
modulator of mPGES-1 expression as already reported.
[21;22;141;143]
 Hence, 
encouraged by these results, we decided to complete the synthesis of PM-
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derivatives, suggested by Ludi, characterized by amido-aromatic appendages 
on the 3-bromo γ-hydroxybutenolide moiety. Indeed, the presence of the 
brominate γ-hydroxybutenolide, accepted by Ludi, was selected as scaffold in 
order to simplify the synthetic approach. 
 
3.1. Chemistry 
As above reported, in order to simplify some crucial structural features of PM 
5 and consequently the synthetic strategy, we decided to use the 3-bromo 
butenolide scaffold, which allowed us to select the commercially available 
mucobromic acid 33 as starting material. Concerning the decorations on C-4 
position of the parent molecule, it was replaced by several molecular 
fragments selected from the database connected to the Ludi software. From a 
structural point of view, the new generation of compounds, possessing more 
complex ammido-aromatic fragments linked to the hydroxybutenolide 






















Scheme 3. Retro-synthetic approach for the synthesis of the new PM-derivatives  
41a-f and 41a-e. 
On the basis of the retro-synthetic analysis (Scheme 3), we decided to 
construct the amido-aromatic appendages through a reaction of ammidation 
starting from the appropriate ammines a-f and carboxylic acids 43 and 44. As 
next step, these advanced intermediates should be linked to the MEM-
protected mucobromic acid 34 through a Suzuki reaction. Thus, a final 
deprotection step could afford the desired products (Chart 8). In any case to 
drive successfully the synthetic strategy each step required to be accurately 
set. 
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In more detail, in order to reduce the polarity of the ammido-aromatic 
intermediates and make easier the purification step on silica columns, as first 
we converted the boronic acids 43 and 44 in the corresponding pinacol esters 
45 and 46. These last were subjected to amidation reaction with the 
appropriate ammine a-f, using the same protocol applied in peptide synthesis. 
In our specific case, we used triethylamine (TEA) as base, N-
hydroxybenzotriazole (HOBt) and N,N'-dicyclohexylcarbodiimide (DIC) as 
















































































Scheme 4. Synthetic protocol to generate derivatives 41a-f and 42a-e. 
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After purification on silica gel, the synthetic scheme implied a Suzuki 
coupling between these advanced intermediates and the MEM-protected 3-
bromo-γ-hydroxybutenolide scaffold 34 that afforded the protected adducts 
49a-f and 50a-e (Scheme 4). Indeed, as for the synthesis of 6-analogues, also 
in this case, it was necessary to protect the mucobromic acid 33 as MEM-
derivative because of the instability of this ring in basic environment, as 
already explained in Chapter 2. We followed the previously optimized 
experimental conditions and, in order to speed up the reaction, we took 
advantages on microwave heating.  
The last step, consisting in the removal of the protecting MEM group, using a 
solution of TFA/TIS/H2O 95:2.5:2.5, afforded our products in good yield 
together with lower amounts of bis-substituted adducts as major by-products.  
The new collection of PM-analogues (Chart 8) obtained is currently under 
biological studies in the laboratories of Professor Oliver Werz (Germany). The 
results of this investigation could help us to individuate new potential 
inhibitors of mPGES-1 expression and to trace the guidelines for further 
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Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase 
(mPGES)-1, 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP): 
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Taking into account the interest shown by scientific community on mPGES-1 
enzyme as promising anti-inflammatory target, we decided to direct our 
research towards the identification of new molecular platforms able to directly 
interact with this target. For this aim, as last step of this project, we focused 
the attention on the design and synthesis of molecules potentially able to 
selectively block the activity of mPGES-1. To rapidly direct the synthesis of 
the most promising new inhibitors, we took advantages of in silico screening. 
Specifically, we designed twenty-six new triazole-based compounds (Chart 9) 
in accordance with the pocket binding requirements of the human mPGES-1 
enzyme. The choice of this scaffold was due to the possibility of applying 
‘click chemistry’ reaction that are known to enable rapid generation of 
molecular collections in a few steps starting from a wide variety of reactants. 
That is perfect for medicinal chemistry project. According with ligand 
efficiency values (Figure 15), coming from docking calculations, we 
performed the synthesis of fifteen compounds that, at least in theory, showed 
to be more efficient in inhibiting mPGES-1. As expected by molecular 
docking data, the biological evaluation of these selected compounds disclosed 
a new interesting mPGES-1 inhibitor along with two relevant hits, 70 and 57, 
that shown to be able to interact with two extremely important enzymes 
involved in the arachidonic acid cascade: 5-LO and FLAP respectively. In 
more details, compound 54 displayed selectivity for mPGES-1 with an IC50 
value of 3.2 µM, while compound 57 apparently acts as FLAP inhibitor (IC50 
= 0.41 µM). Finally, compound 70 showed a dual inhibitory activity on 5-LO 
and mPGES-1 (5-LO: IC50 = 0.8 µM; mPGES-1: IC50 = 11.7 µM) that could 
be a really promising strategy to improve the anti-inflammatory activity and, 
in the same time, to reduce the possible side effects that could arise from the 
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4.1. Molecular docking studies 
The first problem we had to face at the beginning of the design phase was the 
lack, in Protein Data Bank (PDB), of the crystallographic structure of the 
target enzyme in the bioactive conformation. Indeed, even if Jegerschöld et al. 





 it has been demonstrated that the open form of 
the protein represents the productive enzyme. Consequently the absence of 3D 
X-ray crystal structure of open mPGES-1 conformation with a substrate or an 
inhibitor bound has represented the major difficulty for the rational design of 
new specific inhibitors, making the classical receptor-based approach quite 
challenging. That has stimulated many efforts for identifying the key 





 and 3D-quantitative structure activity (QSAR) 
analysis,
[146;147]





molecular modeling and dynamics simulation
[149]
 and site-direct mutagenesis 
studies. As reported by Mancini et al.
[46]
 these efforts have led to the 
identification of several classes of mPGES-1 inhibitors: fatty acids and PGH2 
analogues,
[87]





nonacidic agents and other inhibitors.
[148]
 Considering as starting point the ring 
size of fatty acids and PGH2 analogues, the well known peculiarity of indole 
based agents, such as the simultaneous contributions to the inhibitory activity 
on mPGES-1 of hydrophobic and electrostatic effects, we designed new 
triazole nucleus templates as potential scaffold for anti-inflammatory drugs. 
We designed a small set of compounds (Chart 9), decorating a di-substituted 
triazole ring, taking into account both the synthetic accessibility and the 
compatibility of substituents in positions 1 and 4 of the scaffold with the 
binding requirements of the pocket situated in the region at the interface of the 
two mPGES-1 subunits. Specifically, we gradually increased length, size, 
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Chart 9. Chemical structures of compounds 51-76 utilized for molecular docking 
studies. 
In order to identify the key structural features necessary for mPGES-1 
inhibition, we performed an in silico screening by molecular docking using 
AutoDock 3.0.5 software
[108]
 of a small set of molecules. Because of the 
impossibility to employ the crystallographic structure of mPGES-1, for our 
docking calculation we used the MGST-1 structure solved by Hebert et al. in 
2006.
[150]
 Indeed, like our target, it is an omotrimer, belonging to MAPEG 
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family, with the transmembrane hydrophobic portion, furthermore it has GSH 
as co-factor and showed the 38% of homology sequence with mPGES-1.
[39]
 
Recently the structure-based drug design targeting mPGES-1 has been 
facilitated by work of Hamza et al.
[149] 
that have described the PGH2 binding 
to the mPGES-1-GSH complex. In more details, as also demonstrated by site 
direct mutagenesis, the natural ligand, at the interface of each mPGES-1 
monomer, establishes a strong salt bridge between its carboxylate group and 
the highly conserved Arg110 in the MAPEG family, and interacts with Arg70, 
Asn74, Arg73, Glu77, Tyr117, Leu121, Arg122, Arg126, Thr129, Arg110, 
His72, Lys26, Leu69 and Ile125. Taking into account the considerations 
above, we referred to the sequence alignment of these two MAPEG super 






















Table 2. List of the corresponding amino acids present both in mPGES-1  
and MGST-1 catalytic sites. 
To individuate the compounds that, at least in theory, could have the most 
favorable binding energy with the target, we took into account the theoretical 
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affinities of the designed compounds 51-76 calculated by docking (Figure 15), 
reported as the most favorable MGST-1 free binding energy and ligand 
efficiency
[151-153]
 (binding energy for heavy atom molecular ΔG/NHA).  
 
Figure 15. Calculated affinities and ligand efficiency of 
compounds 51-76 with MGST-1. 
 The above in silico results suggested the synthesis of compounds 54, 56-58, 
61, 64-65, 67-68, 70-74 and 76, all showing the lowest free energy of binding 
and the best ligand efficiency (Ebinding  lower than of 9 kcal/mol and ΔG/NHA 
deeper than -0.24 kcal/mol·NHA) as starting point for obtaining preliminary 
experimental results.  
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Particularly interesting were the in silico screening data concerning two 
compounds, 54 and 70 (Figure 16), which emerged as promising mPGES-1 
inhibitors and trace the features of new potential anti-inflammatory drugs. 
More specifically, both compounds disclosed a similar binding mode at the 
interface of the target monomer. Our proposed poses are in agreement with the 
model reported by Hamza et al.
23
 In fact, the compounds make interactions 
with residues considered critical for PGH2 binding, such as the hydrogen 
bonds with the carboxylic group in 54 and 70 with the highly conserved 
Arg113 in MGST-1 (Arg110mPGES-1), guaranteeing, at least in theory, the 
enzyme binding specificity, as well as van der Waals and other interactions 
with residues of active site - the cation-π interaction with Lys67, Arg72 and 
Arg196 for 54 and with Lys67 and Arg196 for 70.  
 
Figure 16. 3D model of interactions of compounds 54 (A) and 70 (B) with the MGST-
1 binding site. 
 
4.2. Chemistry 
Concerning the synthesis of the fifteen compounds traced by virtual screening 
calculations, the retro-synthetic analysis suggested us to obtain the triazole 
ring through a 1,3 dipolar cycloaddition reaction among appropriate terminal 
alkynes and azides. Finally, to obtain the desired compounds, the triazole 
adduct had to be subjected to a Suzuki coupling reaction (Scheme 5).  
Specifically, for the synthesis of compounds 54, 56-58, 61, 64-65, 67-68, 70-
72, 74 and 76 we utilized the synthetic procedure outlined in Scheme 6. 
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Except for 61, we took advantages of 1,3-dipolar cycloaddition reaction (click 
reaction) among appropriate terminal alkynes and azides to generate the 
triazole intermediates 80-81, 85-87 and 89 that were successively subjected to 
the Suzuki cross-coupling reaction with the appropriate commercially 




















Scheme 5. Retro-synthetic approach for the synthesis of the triazole  
derivatives 51-76. 
Concerning the formation of triazole ring, we performed two different 
strategies on the basis of the availability of the starting reactants. In more 
details, when we started from the commercially available azide 77, the 
traditional protocol for 1,3-dipolar cycloaddition at room temperature for 18 h 
in presence of CuSO4 as catalyst and sodium ascorbate in a mixture of t-
BuOH/H2O 1:1 was used (Scheme 6a).
[116]
 On the contrary, when the azides 
were generated in situ with sodium azide starting from the corresponding 
halides, the microwave irradiation technique provided a faster way to obtain 
the desired triazole intermediates 85-87 (Scheme 6b) in a one pot reaction.
[154]
 
Different reaction conditions have been tested to finally select the better ones. 
The best results were obtained setting the microwaves at 200 W and 250 psi 
and conducting the reaction at 125°C for 30 minutes. 
The synthesis of intermediate 89 required a different procedure owing to the 
presence of the sulfonyl functionality which is a strong electron-withdrawing 
group that could negatively affect the reaction outcome. Indeed, the copper-
catalyzed coupling reaction of azides with alkynes (Figure 17) was proved to 
firstly produce 5-cuprated N-substituted triazole intermediates (A) whose 
stability is governed by various factors including the type of azides and 
alkynes, the reaction medium and the temperature. In this frame particularly 
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bond is stable, and the corresponding 1,2,3-triazoles are easily obtained. On 
the contrary, when R1 is a strong electron-withdrawing group, such as sulfonyl 
group, the electron density on the N
1





 bond is readily cleaved in favour of a variety of by-products rather 























































































Reagents and conditions: (a) CuSO4, sodium ascorbate, H2O/t-BuOH 1:1, r.t., overnight; (b) CuSO4, 
Cu(0), NaN3, t-BuOH/H2O 1:1, MW, 30 min; (c)  CuI, 2,6 lutidine, CHCl3 dry, 12h, 0°C (d) C6H5COCl, 
DMF dry, reflux, overnight; (e) RB(OH)2  a-i, CsF, Pd(dppf)Cl2, H2O/THF, MW, 20-30 min. 
Scheme 6. Synthetic strategy for the synthesis of compounds  
54, 56-58, 61, 64-65, 67-68, 70-72, 74 and 76. 
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However, we were able to obtain the desired sulfonyl triazole intermediate 89, 
carrying out the cycloaddition between 1-bromo-4-ethynylbenzene 79 and 4-
carboxybenzenesulfonazide 88 in dry chloroform at 0° C in presence of 2,6-































Figure 17. Copper-catalyzed cycloaddition of sulfonyl azides with alkynes and 
opening process of triazoles. 
As we can easily note, all the strategies employed to obtain the triazole ring 
need of the presence of copper as catalyst which seems to be essential for the 
regioselective formation of the desired 1,4-disubstitued triazoles. 
The triazole adducts 81, 85-87 and 89, obtained in the first step, were finally 
subjected to the Suzuki cross-coupling reaction with the appropriate boronic 
acids a-i following the experimental conditions previously optimized by 
us,
[141]
 implying for the use of Pd(dppf)Cl2 as catalyst and CsF as base in a 
mixture of THF/H2O 1:1, under microwaves irradiation; the desired final 
compounds 54, 56-58, 64-65, 67-68, 70-72, 74 and 76 (Chart 9) were obtained 
in satisfactory yields.  
On the contrary, compound 61 was obtained submitting the triazole 80 to 
direct acylation with benzoyl chloride in DMF as solvent (Scheme 6). 
 
Risults and Discussion_____________________________________________ 
- 72 - 
 
Finally, in order to synthesize compound 73, we took advantages of a 
multicomponent one-pot reaction between phenyl-1-propyne 90 and 
azidomethyl phenyl sulfide 77 in presence of CuI-N-bromosuccinimide 
(NBS); this step provided the desired 1,4,5-trisubstitued-1,2,3-triazole 91 
bearing a iodine atom at C-5 position.
[158]
 In the last step, the triazole 
intermediate 91 was subjected to the Suzuki cross-coupling reaction with 4-

















bReagents and conditions: (a) CuI, DIPEA, NBS, THF, r.t., 4h; (b) CsF, Pd(dppf)Cl2, H2O/THF, MW, 30 
min. 
Scheme 7. Synthetic strategy for the synthesis of compound 73. 
Concerning the mechanism involved in the formation of the 5-iodo-1,2,3-
triazole scaffold, it has been demonstrated that the oxidation–reduction 
reaction between NBS and CuI is the crucial step. Indeed, it is responsible for 
the in situ generation of I
+
, which is trapped by the carbon anion intermediate 
















Figure 18. Mechanism involved in the formation of 5-iodo-1,2,3-triazole scaffold. 
During these processes, the Cu
+
 do not suffer oxidation; instead, it acts as 
catalyst for the click reaction. Consequently, catalytic amount of CuI plays 
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double fundamental roles. As first it provides Cu
+
 which is the catalyst, 
necessary in the Huisgen’s cycloaddition between azide and terminal alkynes 
for the regioselective production of the 1,2,3-triazole 1,4-disubstitued. 
Furthermore it provides I
- 





The biological screening of the synthesized molecules was made in 
collaboration with Professor Oliver Werz of the University of Tuebingen 
(Germany). 
In more details, to assess the ability of the selected compounds 54, 56-58, 61, 
64-65, 67-68, 70-74 and 76 to interfere with the activity of mPGES-1, a cell-
free assay using the microsomal fractions of IL-1β-stimulated A549 cells, as 
source for mPGES-1, was applied. In a first screening round all compounds, 
solubilised in dimethylsulfoxide (DMSO), were tested at a concentration of 10 
µM. The mPGES-1 inhibitor compound MK-886 8 (IC50 = 2.4 µM)
[101]
 was 
used as reference control, and DMSO (0.3%, v/v) was used as vehicle control. 
Compounds 54, 57, 70 and 73 significantly inhibited mPGES-1 activity, 
whereas all other derivatives were essentially inactive (Table 3).  
Interestingly, these data confirmed the results from the docking studies 
indicating 54 and 70 as mPGES-1 inhibitors. More detailed analysis of 54 in 
concentration-response studies (Figure 19) revealed an IC50 value of 3.2 µM 
and indicated an almost complete inhibition of mPGES-1 activity at 30 µM. In 
contrast to 54, compound 70 failed to entirely suppress mPGES-1 activity and 
the concentration-response curve seemingly reached a plateau with maximum 
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                                   Remaining 
                                       activity 
   IC 50 [µM]                 at 30 µM 
54 3.2 12.0% ± 3.7** 
56 > 30 89.0% ± 2.9 
57 > 30 60.1% ± 4.3** 
58 > 30 78.2% ± 12.8 
61 > 30
 
76.1% ± 7.9 
64 > 30 73.6% ± 8.0 
65 > 30 96.8% ± 0.5 
67 > 30 91.9% ± 8.1 
68 > 30 87.9% ± 8.4 
70 > 30 59.8% ± 7.2** 
71 > 30 85.0% ± 9.3 
72 > 30 90.0% ± 6.8 
73 > 30 72.1% ± 4.2* 
74 > 30 98.2% ± 7.3 
76 > 30 88.7% ± 2.7 
Table 3. Effect of test compounds 54, 56-58, 61, 64-65, 67-68, 70-74 and 76 on the 
activity of mPGES-1. Data are given as mean +/- S.E., n=4-6. *p < 0.05, **p < 0.01. 
Previous studies on acidic mPGES-1 inhibitors showed that such compounds 
often interact also with other enzymes within the arachidonic acid cascade, 
such as 5-LO or FLAP.
[89;93]
 On the other hand, interference with 5-LO or 
FLAP, the key enzymes in the formation of LTs from arachidonic acid, is 
considered a valuable characteristic of a given mPGES-1 inhibitor, because 
dual suppression of PGE2 and LT formation might be superior over single 
interference in terms of higher anti-inflammatory efficacy as well as in terms 
of reduced side effects.
[47]
 Thus, the test compounds were further analysed for 
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inhibition of 5-LO activity, in a cell-free assay using isolated human 
recombinant 5-LO as enzyme source. The well-recognized 5-LO inhibitor (E)-
N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide (BWA4C)
[159]
 was used 
as positive control, DMSO (0.3%, v/v) was used as vehicle control. 
Intriguingly, among the test compounds, 70 was the most active derivative 
with IC50 = 0.8 µM, followed by 71, 54 and 67 (Table 4, IC50 = 3.3 µM, 7.2 
µM, and 8.3 µM, respectively) that all inhibited 5-LO activity in a 
concentration-dependent manner. Also 56, 64, 73 and 76 significantly 
inhibited 5-LO at a concentration of 30 µM but the magnitude of inhibition did 
not exceed 50% (Table 4) and thus IC50 values could not be determined.   
compound 20 [µM]






































































Figure 19. Inhibition of mPGES-1. Concentration-response curves of compounds 54 
and 70 for inhibition of mPGES-1 activity in microsomal preparations of IL-1β-
stimulated A549 cells. 
Finally, the potential inhibitory effect of the test compounds 54, 56-58, 61, 64-
65, 67-68, 70-74 and 76 on FLAP in human neutrophils activated by 
ionophore A23187 was tested using compound MK-886 8 (IC50 for FLAP in 
neutrophils approx. 70 nM)
[102]
 as control and DMSO (0.3%, v/v) as vehicle 
control. As shown in Table 4, compound 70 revealed the best inhibitory 
activity (IC50 = 0.6 µM) followed by compound 71 (IC50 = 2.8 µM). A 
remarkable and concentration-dependent suppression of cellular 5-LO 
products synthesis was found for 57 with IC50 = 0.4 µM and also for 56 and 74 
(IC50 = 0.9 and 1.7 µM respectively) although the compounds hardly inhibited 
5-LO in cell-free assay. This suggests that, to suppress 5-LO products 
Comp und 54 [µM] Compound 70 [µM] 
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formation, 56, 57 and 74, in intact cells, may primarily act on other targets 
different from 5-LO enzyme, presumably on FLAP. Such mechanism may 
also be attributed to compounds 61 and 73, though with lower potencies (IC50 
= 8.9 and 6.1 µM, respectively).  
Comp. 
5-LO activity;  
cell-free 
 
IC 50 [µM]              Remaining  
                              activity at 30 µM 
5-LO activity; intact 
neutrophils 
 
IC 50 [µM]              Remaining  
                              activity at 30 µM 
54 6.7 20.0% ± 0.9** 9.2 20.1% ± 11.0** 
56 > 30 62.3% ± 1.4** 0.9 34.8% ± 7.0** 
a)
 
57 27 48.8% ± 0.4** 0.4 1.1% ± 0.3** 
a)
 
58 > 30 82.9% ± 0.9 > 30 85.7% ± 3.5 
61 > 30
 80.8% ± 5.3 9.3
 
14.6% ± 5.2** 
64 > 30 58.4% ± 12.7* > 30 70.2% ± 8.5 
65 > 30 77.4% ± 0.9 > 30 79.9% ± 10.7 
67 8.8 10.1% ± 4.6** > 30 52.7% ± 15.0* 
68 > 30 82.5% ± 4.4 > 30 92.1% ± 8.1 
70 0.8 13.6% ± 2.8**
 a)
 0.6 3.5% ± 2.5**
 a)
 
71 4.1 5.1% ± 0.8** 2.8 21.2% ± 4.3**
 a)
 
72 > 30 78.4% ± 10.3 > 30 84.5% ± 3.4 
73 > 30 57.3% ± 1.2** 6.0 17.3% ± 2.5**
 a)
 
74 > 30 60.7% ± 10.0 1.7 22.0% ± 2.6** 
a)
 
76 > 30 59.2% ± 6.4* > 30 70.1% ± 9.0 
 
a) remaining activity at 10 µM 
 
Table 4. Effect of test compounds on the activity of 5-LO in cell-free and cell-based 
(intact neutrophils) assays. Data given as mean +/- S.E., n=4-6. 
 *p < 0.05, **p < 0.01. 
All in all, based on the outcomes of the biological activity data, 54 is the most 
efficient inhibitor of mPGES-1, 57 might act as a FLAP inhibitor, while 70 
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could be a potent direct 5-LO inhibitor, besides moderate inhibition of 
mPGES-1. Hence, we aimed to rationalize the results through molecular 
modeling studies. As preliminary remarked, it should be put in evidence that 
compounds 54 and 57, inhibiting the two MAPEG family members, showed 
quite similar chemical features; on the contrary, the more encumbering ligand 








Figure 20. Chemical structure of MK-591 and 3D model of interactions of 57 with 
FLAP. The figure highlights similar interactions for both 57 and MK-591 with 
arachidonic acid-binding site. 
For our calculations we used the three dimensional structure of FLAP in 
complex with the inhibitor MK591 solved by Ferguson et al.
[160]
 in 2007 (PDB 
ID code 2Q7M). Owing to the lack of crystal structure information on 5-LO, 
we used a 15-LO
[161]
 (PDB ID code 1lox) enzyme, presenting the highest 
sequence similarity (38% identity with human 5-LO) among the dioxygenase 
family (8-, 9-, 11-, 12-LO).  
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Taking into account the considerations reported above for the MGST-1 
enzyme, also in the case of FLAP, the binding specificity was conferred by the 
H-bond with the Lys116. In our proposed pose, 57 (Figure 20) interacts not 
only with the fundamental amino acids, but also adopts the equivalent spatial 
disposition of the co-crystallized inhibitor,
[161]
 maintaining the same 
interactions network. Moreover, the phenyl group in R1 forms a π-π stacking 
with Phe25.  
Three different classes of inhibitors can be generally considered for 5-LO:
 
(1) 
antioxidant agents interfering with the redox catalytic cycle of the enzyme, (2) 
iron-chelating agents and (3) nonredox-type inhibitors, which compete with 
arachidonic acid for the binding to the enzyme.
[162]
 In our docking studies, we 
supposed that 70 acts as nonredox-type LO inhibitor.  
As described for mPGES-1, the rationalization of the 5-LO binding mode was 
obtained considering the fundamental amino acids in the active site of the 
enzyme as reported by Wouters et al.,
[163]
 taking in consideration the specific 
polar interaction of the carboxylate moiety of arachidonic acid with Lys4095-L0 
(Arg40315-LO).  
For compound 70, we obtained two different conformation families, 
accounting for two independent high affinity binding modes (Figure 21A-B). 
In both the conformations, the specific interaction with Arg403 was 
maintained. In more details, in the first conformation type (Figure 21A) the 
phenyl group in R1 shows a cation-π interaction, while in the second 
conformation type (Figure 21B), the same cation-π interaction with Arg403 
was exerted by the naphtyl group in R2 present in the alternative conformation. 
In the latter case, the oxygen atom in R2 forms an additional H-bond with the 
positively charged (Arg403) residue. Even if R1 and R2 are located on the 
opposite sites of the target pocket, the other interactions with the receptor 
counterpart remain unmodified and are in accordance with the structural 
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requirements indicated by Wouters et al.,
[163]
 that is two hydrophobic groups, 
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Optimization Processes on Compound 54, the 
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Encouraged by the interesting biological results obtained from the triazole 
derivatives 54, 56-58, 61, 64-65, 67-68, 70-74 and 76 that allowed us to 
identify some potential inhibitors of mPGES-1 enzyme, in the last part of this 
project we directed our attention to a new hit, compound 54, that emerged as a 
selective inhibitor of the target enzyme (IC50 = 3.2 µM). In order to improve 
its biological activity, we decided to rely on some well-reasoned structural 
changes of the basic molecule (Chart 10). In more details, taking into 
consideration the model of interaction between compound 54 and its target 
enzyme (Figure 16A), we decided to keep unchanged the basic scaffold of 
compound 54 bearing an aromatic moiety with a carboxylic function in 1-
position of the triazole ring and a biphenylic system linked on C-4 of the 
scaffold. In fact, the carboxylic group seems to be responsible for the mPGES-
1-binding specificity as it was considered crucial for the interaction with 
Arg113, the key residue involved in PGH2 binding. On the other hand, the 
biphenyl system seems to project the appropriate substituent at the right 
distance to interact with polar amino acids present in the upper side of the 












































































Chart 10. Collection of compound 54-derivatives. 
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On the basis of these preliminary considerations, as start we decided to vary 
the type and the position of the substituents on the second ring of the biphenyl 
system in order to explore more chemical space. Moreover, we also proved to 
replace one phenyl group of the biphenyl with an aromatic eterocycle, like 
tiophene (compound 93m) in order to definitively establish the crucial role 
played by the biphenyl system in the interaction with enzyme active site. 
 
5.1. Chemistry 
Concerning the synthesis of analogues 93b-d and 93h-n, as already reported 
for the synthesis of the first generation of triazole derivatives 54, 56-58, 61, 
64-65, 67-68, 70-74 and 76, the retro-synthetic approach suggested us to 
obtain the triazole ring through the above described 1,3 dipolar cycloaddition 
among the appropriate terminal alkynes and azides, while to generate the 
decorated biphenyl system we could rely on the versatile Suzuki coupling 






















Scheme 8. Retro-synthetic approach for the synthesis of derivatives 93b-d and 93h-n. 
In more details, the triazole ring was generated as usual in a one pot reaction, 
taking advantages on the microwaves technology that allowed us to obtain in 
situ the azide starting from the corresponding halide and sodium azide 
(Scheme 9). Also in this case the 1,3-dipolar cycloaddition required the 
presence of Cu(I) as catalyst for the reaction regiocontrol.
[116]
 The triazole 
intermediate 87, obtained from the first step, was further subjected to the 
Suzuki cross-coupling reaction with the appropriate boronic acid b-d, h-n 
following the experimental conditions previously optimized by us,
[141]
 
requiring the use of Pd(dppf)Cl2 as catalyst and CsF as base in a mixture 
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THF/H2O 1:1, under microwaves irradiation; the desired compounds 93b-d 
































































































































Scheme 9. Synthetic protocol employed to generate derivatives 93b-d and 93h-n. 
The boronic acids employed in the last step, are all commercially available 
except for pinacol esters j and n. These last were obtained, as shown in 
Scheme 9, starting from the appropriate boronic acids 43 and 94 which were 
first protected as pinacol esters 45 and 95 to reduce the polarity of the 
intermediates and make easier the purification step on silica column. Finally, 
to obtain the advanced intermediate n, the pinacol ester 95 was subjected to a 
reductive amination reaction with morpholin 96, while to generate the amidic 
derivate j, the pinacol ester 45 was subjected to the reaction of amidation with 
morpholin 96 using TEA as base, HOBt and DIC as carboxylate activators and 
DMF as solvent. 
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The synthesized compounds 93b-d and 93h-n are currently under biological 
investigation in the laboratories of Professor Oliver Werz of the University of 
Tuebingen (Germany) and, in our opinion, the results could be very useful to 
trace clearer guidelines for further structural optimization which could lead to 
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In conclusion, in the course of the present project an efficient approach toward 
the discovery of new agents able to target mPGES-1 enzyme has been 
outlined. In more details, starting from compound 6, emerged as promising 
inhibitor of mPGES-1 expression, and basing on the experience gained in 
handling the densely functionalized γ-hydroxybutenolide scaffold, we were 
able to discover new hits possessing a better biological profile compared to the 
lead molecule 6. 
Furthermore, in order to explore more chemical space useful to discover new 
and more effective inhibitors of mPGES-1 expression as promising anti-
inflammatory candidates, a new collection of γ-hydroxy-butenolides bearing 
amido-aromatic appendages has been developed and their biological 
evaluation is still in progress. 
Concerning the discovery of new agents able to directly interfere with the 
target enzyme, taking advantages of molecular modelling studies and basing 
either on the highly efficient and reliable ‘click chemistry’ approach as well as 
the versatile Suzuki cross-coupling reaction, a collection of triazole based 
compounds was successfully realized. Biological studies, performed on these 
molecules in collaboration with professor Oliver Werz’ group, allowed us to 
identify three interesting molecules as promising candidates for the discovery 
of potent and safer anti-inflammatory drugs: compound 54 displaying a 
selective inhibitory activity towards mPGES-1 (IC50 = 3.2 µM), compound 70 
that dually inhibits 5-LO and mPGES-1 and compound 57 acting as FLAP 
inhibitor (IC50 = 0.4 µM).  
Finally, as last task of this project we focused our efforts to amplify chemical 
diversity of the triazole scaffold in order to gain a clear structure-activity 
profile useful for further lead optimization process. 
In the course of this project, in addition to mastering the main spectroscopic 
and spectrometric techniques of the structural elucidation, I had the 
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organic synthesis, such us Suzuki cross-coupling reaction, a versatile process 
for carbon-carbon bond formation, 1,3-dipolar cycloaddition reaction (click 
reaction), a powerful tool in the hands of chemists for rapid and easy 
generation of large library of compounds, and finally photooxydation reaction 
that is potentially able to furnish a lot of interesting compounds of heterocycle 
nature. 
Furthermore, as some of the synthesis presented here were carried out with 
microwaves heating, I became skilful in the use of this technology. Finally, I 
also experienced the most recent and advanced computer aided methods 
applied for drug design processes that allowed to rapidly direct the synthetic 
efforts towards those molecules showing, at least in theory, the best affinity 
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6.1. LUDI design 
The Ludi module of Insight II (Accelrys, San Diego, CA) was used for the in 
silico design of compounds 41a-f and 42a-e. Computation was performed on a 
Silicon Graphics Indigo 2 workstation equipped with a R10000 processor. The 
3D complex structure bee venom PLA2 (1POC)-PM
4
 was imported into the 
graphic modeling program Insight II; the tetracyclic portion of PM 5 was 
deleted from the active site of the above-mentioned adduct, whereas the 
tridimensional coordinates of the γ-hydroxybutenolide ring were kept 
unaltered. On this data set, LUDI performed a database screening on the 
User_link_library (provided by Accelerys version 1998 and 2000.2) to select 
appropriate aromatic and heteroaromatic fragments to replace the sesterterpene 
skeleton of PM 5 by linking the γ-hydroxybutenolide ring. The value of the 
maximum RMS deviation was fixed at 0.4 Å, the lipo weight was set at 10, the 
H bond weight was set at 1 and the value of the minimum separation was 
definitively 3.00. The other parameters were used as standard default. For each 
fragment, the LUDI score was calculated by means of the scoring function 
mentioned as energy estimate_3. 
 
6.2. Methods and materials 
All water and air sensitive reactions were carried out under an inert 
atmosphere (N2 or Ar) in oven- or flame-dried glassware. DCM and THF were 
distilled from CaH2 immediately prior to use. Water was degassed under 
vacuum (10 mbar). All reagents were used from commercial sources without 
any further purification.  
Microwave reactions were performed on a CEM Discover® single mode 
platform using 10 mL pressurized vials.  
Reactions were monitored on silica gel 60 F254 (Merck) plates and visualized 
with potassium permanganate or ninhydrin and under UV (λ = 254 nm, 365 
nm). Flash column chromatography was performed using Merck 60/230–400 
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mesh silica gel. Analytical and semi-preparative reverse-phase HPLC 
purifications were performed on a Waters instrument using Jupiter C-18 
column (250 · 4.60 mm, 5 µm, 300 Å; 250 · 10.00 mm, 10 µm, 300 Å, 
respectively). Purity grade of final products was determined on a Agilent 1100 
HPLC using analytical reverse-phase columns (Method: Jupiter C-18, 250 · 
4.60 mm, 5 µm, 300 Å). Reaction yields refer to chromatographically and 
spectroscopically pure products. Proton-detected (
1
H, HMBC, HSQC) and 
carbon-detected NMR spectra were recorded on Bruker instruments of Avance 
series operating at 300, 500 and 600 MHz and 75, 125 and 150 MHz, 
respectively. Chemical shifts are expressed in parts per million (ppm) on the 
delta (δ) scale. The solvent peak was used as internal reference: for 
1
H NMR 
CDCl3 = 7.26 ppm and CD3OD = 3.34 ppm; for 
13
C NMR: CDCl3 = 77.0 ppm 
and CD3OD = 47.7 ppm. Multiplicities are reported as follows: s, singlet; d, 
doublet; t, triplet; m, multiplet; dd, doublet of doublets.  
Electrospray mass spectrometry (ES-MS) was performed on a LCQ DECA 
ThermoQuest (San Josè, California, USA) mass spectrometer. 
 [5,6,8,11,12,14,15(n)-3H] PGE2 and [9,10-3H]oleic acid were purchased from 
Amersham Biosciences (Barcelona, Spain). The rest of reagents were from 
Sigma (St. Louis, MO, USA). Escherichia coli strain CECT 101 was a gift 
from Professor Uruburu, Department of Microbiology, University of Valencia, 
Spain.  
 
6.2.1. Photooxidation of 3-bromofuran 36 
A two neck flask with 150 mL of dry DCM was cooled to -78 °C. Under 
stirring, 3-bromofuran 36 (612 μL, 6.8 mmol) and finely powdered 
polystyrene-bound rose bengal catalyst (150 mg) were added. Then the base (2 
equiv.) was introduced and the oxygen bubbled for 15 min. After the 300 W 
lamp was turned on, the solution was stirred at -78 °C in a continuous flow of 
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allowed to warm to 0 °C, the catalyst was filtered off and the solution rapidly 
washed with an aqueous solution of HCl 1M (150 mL). The aqueous layer was 
extracted with DCM (3 x 100 mL). The organics were finally dried with 
Na2SO4, filtered and concentrated in vacuo. The residue was purified on a 
semipreparative C-18 reverse-phase-HPLC column, leaving the desired 
product (37 or 39) as an oil. 
4-Bromo-5-hydroxy-5H-furan-2-one 37. 
1
H-NMR (300 MHz, CDCl3): δ 
6.42 (1H, s), 6.04 (1H, s). 
13
C-NMR (75 MHz, CDCl3): δ 
169.4, 148.1, 124.0, 99.6. ES-MS calcd. for C4H2BrO3: [M-H]
-
 
176.93 and 178.92 (1:1); found 176.9 and 178.9 (1:1). 
3-Bromo-5-hydroxy-5H-furan-2-one 39. 
1
H-NMR (300 MHz, CDCl3): δ 
7.34 (1H, d, J=1.5 Hz), 6.24 (1H, d, J=1.5 Hz). 
13
C-NMR (75 
MHz, CDCl3): δ 167.7, 149.3, 117.8, 98.7. ES-MS calcd. for 
C4H2BrO3: [M-H]
-
 176.93 and 178.92 (1:1); found 176.8 and 
178.8 (1:1). 
 
6.2.2. Protection of 37 and 39 as THP ethers 
A solution of 37 or 39 (40 mg, 0.22 mmol) and DHP (51 μL, 0.56 mmol) in 4 
ml of dry DCM was cooled to 0 °C in ice-bath. Upon stirring p-toluensulfonic 
acid monohydrate (192 mg, 1.12 mmol) was slowly added keeping the 
temperature at 0 °C for 10 min. The mixture was allowed to warm to room 
temperature and the reaction was stopped after 4 h. The solution was diluted 
with 20 mL of DCM and then washed with a 1:1:2 mixture of saturated NaCl, 
saturated NaHCO3 and water (20 mL). The organic layer was dried, filtered 
and concentrated in vacuo. The crude brown oil obtained was purified by flash 
chromatography (100% n-hexane to 30% diethyl ether/n-hexane) to give, 
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4-Bromo-5-(tetrahydropyran-2-yloxy)-5H-furan-2-one 38. Yield: 95%; 
1
H-
NMR (300 MHz, CDCl3): δ 6.38 (1H, s), 6.10 (1H, s), 5.16 
(1H, s), 3.96-3.90 (1H, m), 3.81-3.75 (1H, m), 1.78-1.54 
(6H, m). 
13
C-NMR (75 MHz, CDCl3): δ 168.7, 148.6, 
124.3, 98.8, 98.4, 64.3, 30.2, 25.4, 19.0. ES-MS calcd. for C9H12BrO4: 
[M+H]
+
 262.98 and 264.98 (1:1); found 262.9 and 264.9 (1:1). 
3-Bromo-5-(tetrahydropyran-2-yloxy)-5H-furan-2-one 40. Yield: 87%; 
1
H-
NMR (300 MHz, CDCl3): δ 7.32 (1H, d, J=1.5 Hz), 6.21 
(1H, d, J=1.5 Hz), 5.12-5.10 (1H, m), 3.87-3.80 (1H, m), 
3.66-3.61 (1H, m), 1.80-1.64 (6H, m). 
13
C-NMR (75 MHz, 
CDCl3): δ 166.5, 147.8, 118.1, 98.2, 95.0, 63.2, 30.1, 25.4, 19.0. ES-MS calcd. 
for C9H12BrO4: [M+H]
+
 262.98 and 264.98 (1:1); found 262.9 and 264.9 (1:1). 
 
6.2.3. Synthesis of 3,4-dibromo-5-(2-methoxy-ethoxymethoxy)-5H-furan-2-
one 34 
Mucobromic acid 33 (100 mg, 0.387 mmol) was dissolved in 10 mL of dry 
DCM and MEM-Cl (66 µL, 0.581 mmol) was added to the solution. DIPEA 
(101 µL, 0.581 mmol) was added dropwise over a period of 15 min. After 4 h, 
the reaction mixture was quenched with 20 mL of HCl 1 M. The aqueous layer 
was extracted with DCM (3 x 30 mL) and the organics were dried with 
Na2SO4, filtered and concentrated in vacuo. The crude dark oil obtained was 
purified by flash chromatography (5% diethyl ether/n-hexane to 20% diethyl 
ether/n-hexane) to give 34 (115 mg, 85% yield): 
 1
H NMR 
δ (300 MHz; CDCl3): δ 6.10 (1H, s), 5.20 (1H, d, J = 7.2 
Hz), 4.87 (1H, d), 3.79 (1H, m), 3.40 (3H, s), 3.60 (1H, 
m), 3.54 (2H, dd); ES-MS calcd. for C8H11Br2O5: [M+H]+ 344.89, 346.89 and 
348.89 (1:2:1); found [M+H]
+
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6.2.4. Esterification of boronic acids 43 and 44 
The boronic acids 43 and 44 (0.667 mmol) were dissolved in 6 mL of ethyl 
acetate and, stirring the solution, pinacol (0.667 mmol) was added. After 4h 
the reaction was stopped adding anhydrous Na2SO4 (1 g) and CaCl2 (1 g). The 
mixture was filtered and concentrated in vacuo (Yield: 91% of 45 and 90% of 
46). 
 
6.2.5. Synthesis of amides: general procedure 
The pinacol ester 45 or 46 (1 equiv.) and the appropriate ammine a-f (2 equiv.) 
were dissolved in DMF. TEA, HOBt and DIC (2 equiv. of each) were added. 
The mixture was leaved at r.t. for 48 hours under stirring. When TLC showed 
the consumption of the pinacol ester, the reaction was stopped adding HCl 1N 
(10 mL). The aqueous phase was extracted with ethyl acetate (3 x 10 mL) and 
the organic phase was washed firstly with a saturate solution of NaHCO3 and 
then with brine. Afterward the organics were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude was purified by flash chromatography (10% 
diethyl ether/n-hexane to 70% diethyl ether/n-hexane).  
Pyrrolidin-1-yl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 47a. Yield: 87%; 
1
H NMR δ (300 MHz; CDCl3): 7.98 (2H, d), 
7.38 (2H, d), 3.59 (2H, t), 3.34 (2H, t), 1.94 (2H, quint), 
1.84 (2H, quint), 1.31 (12H, s). ES-MS calcd. For 
C17H25BNO3: [M+H]
+
 302.18; found 302.1. 
Morpholin-4-yl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 47b. Yield: 83%; 1H NMR δ (300 MHz; CDCl3): 7.89 (2H, d), 
7.35 (2H, d), 4.20 (2H, t), 3.87 (2H, t), 3.79 (4H, m), 
1.32 (12H, s). ES-MS calcd. for C17H25BNO4: [M+H]
+
 















- 100 - 
 
N-Phenyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide 47c. 
Yield: 71%; NMR δ (300 MHz; CDCl3): 7.88 (2H, 
d), 7.42 (2H, d), 7.42-7.36 (5H, m), 1.32 (12H, s).  





Yield: 88%; NMR δ (300 MHz; CDCl3): 7.97 (2H, 
d), 7.33 (2H, d), 7.34-7.28 (5H, m), 4.62 (2H, d), 
1.34 (12H, s). ES-MS calcd. for C20H25BNO3: 
[M+H]
+
 338.18; found 338.1.  
Piperidin-1-yl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 47e. Yield: 90%; NMR δ (300 MHz; CDCl3): 7.93 (2H, d), 7.38 
(2H, d), 3.80 (2H, t), 3.32 (2H, t), 1.66 (4H, quint), 
1.48 (2H, quint), 1.33 (12H, s). ES-MS calcd. for 
C18H27BNO3: [M+H]
+
 316.20; found 316.2. 
Piperazin-1-yl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 47f. Yield: 72%; 
1
H NMR δ (300 MHz; CDCl3): 7.81 (2H, d), 
7.32 (2H, d), 3.79 (2H, t), 3.72 (2H, t), 3.24 (2H, t), 
3.12 (2H, t), 1.47 (9H, s), 1.31 (12H, s). ES-MS 
calcd. for C22H34BN2O5: [M+H]
+
 4178.25; found 
417.2. 
Pyrrolidin-1-yl-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 48a. Yield: 89%; 
1
H NMR δ (300 MHz; CDCl3): 8.06 (1H, s), 
7.87 (1H, d), 7.48 (1H, d), 7.39 (1H, t), 3.63 (2H, t), 
3.47 (2H, t), 2.01 (2H, quint), 1.92 (2H, quint), 1.36 
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302.18; found 302.2. 
Morpholin-4-yl-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-
methanone 48b. Yield: 85%; 
1
H NMR δ (300 MHz; CDCl3): 7.99 (1H, s), 
7.83 (1H, d), 7.45 (1H, d), 7.37 (1H, t), 3.85 (2H, t), 
3.70 (4H, m), 3.52 (2H, t), 1.34 (12H, s). ES-MS calcd. 
for C17H25BNO4: [M+H]
+




H NMR δ (300 MHz; CDCl3): 8.23 
(1H, s), 8.02 (1H, d), 7.92 (1H, d), 7.65 (2H, d), 7.45 
(1H, t), 7.33 (2H, t), 7.11 (1H, t), 1.33 (12H, s).  ES-
MS calcd. for C19H23BNO3: [M+H]
+
 324.17; found 
324.1. 
N-Benzyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide 48d. 
Yield: 89%; NMR δ (300 MHz; CDCl3): 8.31 (1H, 
s), 8.12 (1H, d), 7.83 (1H, d), 7.52 (1H, t), 7.40-
7.35 (3H, m), 7.58 (2H, d), 4.63 (2H, d), 1.33 (12H, 





methanone 48e. Yield: 91%; NMR δ (300 MHz; CDCl3): 7.98 (1H, s), 7.89 
(1H, d), 7.44 (1H, d), 7.37 (1H, t), 3.80 (2H, t), 3.31 
(2H, t), 1.64 (4H, quint), 1.48 (2H, quint), 1.31 (12H, 
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6.2.6. Microwave-assisted Suzuki coupling: general procedure 
In a CEM Discover vial intermediates 34 or 38 or 40 (1 equiv), the appropriate 
boronic acid a-i or 47a-f or 48a-e (1.5 equiv), Pd(dppf)Cl2 (0.03 equiv), 
TBAB (0.5 equiv) and CsF (4 equiv) were placed. Under argon, water (500 
µL) and THF (500 µL) were added. The mixture was irradiated for 3-6 
minutes, setting the power at 200 W, the temperature at 120 °C, the pressure at 
250 psi and the Power Max ON. At the end of the reaction, the vial was cooled 
to 50 °C by gas jet cooling before it was opened. After diluting (10 mL) with 
DCM, 10 mL of an aqueous solution of HCl 1 N was added. The aqueous 
layer was extracted with DCM (3 x 10 mL). The organics were then dried over 
Na2SO4, filtered and concentrated in vacuo. The crude products were purified 
by flash chromatography (10% diethyl ether/n-hexane to 40% diethyl ether/n-
hexane) to furnish compounds 35a-d, 31e-i, 32e-i, 49a-f or 50a-e. 
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[4-(pyrrolidine-1-carbonyl)-
phenyl]-5H-furan-2-one 49a. Yield: 74%; 
1
H-NMR  (300 MHz; CDCl3): 
7.93 (2H, d), 7.52 (2H, d), 6.58 (1H, s), 5.18 (1H, d), 
4.87 (1H, d), 3.83-3.76 (1H, m), 3.69-3.63 (1H, m), 3.58 
(2H, t), 3.41 (3H, s), 3.55-3.40 (4H, m), 1.90-2.05 (4H, 
m); ES-MS calcd. for C19H23BrNO6: [M+H]
+
 440.06 
and 442.06 (1:1); found 440.0 and 442.0 (1:1). 
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[4-(morpholine-4-carbonyl)-
phenyl]-5H-furan-2-one 49b. Yield: 63%; 
1
H-NMR  (300 MHz; CDCl3): 
7.97 (2H, d), 7.48 (2H, d), 6.57 (1H, s), 5.17 (1H, d), 
4.88 (1H, d), 3.97 (4H, m), 3.78-3.73 (3H, m), 3.68-
3.60 (1H, m), 3.56 (2H, t), 3.41 (3H, s), 3.40 (2H, t); 
ES-MS calcd. for C19H23BrNO7: [M+H]
+
 456.06 and 
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4-[4-Bromo-2-(2-methoxy-ethoxymethoxy)-5-oxo-2,5-dihydro-furan-3-yl]-
N-phenyl-benzamide 49c. Yield: 65%; 
1
H-NMR  (300 MHz; CDCl3): 8.05 
(2H, d), 7.49 (2H, d), 7.18 (2H, t), 6.91 (1H, t), 6.79 (2H, 
d), 6.59 (1H, s), 5.19 (1H, d), 4.88 (1H, d), 3.75-3.72 
(1H, m), 3.66-3.63 (1H, m), 3.53 (2H, t), 3.38 (3H, s). 
ES-MS calcd. for C21H21BrNO6: [M+H]
+
 462.05 and 
464.05 (1:1); found 462.6 and 464.6 (1:1). 
N-Benzyl-4-[4-bromo-2-(2-methoxy-ethoxymethoxy)-5-oxo-2,5-dihydro-
furan-3-yl]-benzamide 49d. Yield: 61%; 
1
H-NMR  (300 MHz; CDCl3): 7.86 
(2H, d), 7.47 (2H, d), 7.18 (2H, t), 6.91 (1H, t), 6.79 
(2H, d), 6.57 (1H, s), 5.15 (1H, d), 4.85 (1H, d), 
4.65 (2H, d), 3.75-3.72 (1H, m), 3.66-3.63 (1H, m), 
3.53 (2H, t), 3.38 (3H, s); ES-MS calcd. for 
C22H23BrNO6: [M+H]
+
 476.06 and 478.06 (1:1); 
found 476.4 and 478.4 (1:1). 
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[4-(piperidine-1-carbonyl)-
phenyl]-5H-furan-2-one 49e. Yield: 75%; 
1
H-NMR  (300 MHz; CDCl3): 
7.99 (2H, d), 7.57 (2H, d), 6.58 (1H, s), 5.18 (1H, d), 
4.87 (1H, d), 3.79-3.73 (2H, m), 3.68-3.58 (4H, m), 
3.41 (3H, s), 3.35 (2H, t), 1.76 (4H, m), 1.55 (2H, 
quint); ES-MS calcd. for C20H25BrNO6: [M+H]
+
 454.08 
and 456.08 (1:1); found 454.2 and 456.2 (1:1). 
4-{4-[4-Bromo-2-(2-methoxy-ethoxymethoxy)-5-oxo-2,5-dihydro-furan-3-
yl]-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester 49f. Yield: 59%; 
1
H-NMR  (300 MHz; CDCl3): 7.99 (2H, d), 
7.52 (2H, d), 6.58 (1H, s), 5.17 (1H, d), 4.87 
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3.62 (5H, m), 3.57 (2H, t), 3.41 (3H, s), 1.48 (9H, s); ES-MS calcd. for 
C24H32BrN2O8: [M+H]
+
 555.13 and 557.12 (1:1); found 555.1 and 557.1 (1:1). 
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[3-(pyrrolidine-1-carbonyl)-
phenyl]-dihydro-furan-2-one 50a. Yield: 71%; 
1
H-NMR δ (300 MHz; 
CDCl3): 8.05 (1H, d), 8.01 (1H, s), 7.63 (1H, d), 7.55 
(1H, t), 5.18 (1H, d), 4.87 (1H, d), 3.63 (2H, t), 3.49 
(2H, t), 3.69-3.63 (1H, m), 3.58 (2H, t), 3.41 (3H, s), 
2.19-2.14 (4H, m), 2.03-1.90 (2H, m); ES-MS calcd. for 
C19H23BrNO6: [M+H]
+
 440.06 and 442.06 (1:1); found 
440.1 and 442.1 (1:1).  
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[3-(morpholine-4-carbonyl)-
phenyl]-dihydro-furan-2-one 50b. Yield: 64%; 
1
H-NMR δ (300 MHz; 
CDCl3): 7.95 (1H, s), 7.90 (1H, d), 7.55 (1H, d), 7.44 
(1H, t), 6.56 (1H, s), 5.18 (1H, d), 4.92 (1H, d), 3.99 
(4H, m), 3.81 (2H, t), 3.79-3.74 (1H, m), 3.67-3.62 (1H, 
m), 3.57 (2H, t), 3.41 (3H, s), 3.36 (2H, m); ES-MS 
calcd. for C19H23BrNO7: [M+H]
+
 456.06 and 458.06 
(1:1); found 456.1 and 458.1 (1:1). 
3-[4-Bromo-2-(2-methoxy-ethoxymethoxy)-5-oxo-2,5-dihydro-furan-3-yl]-
N-phenyl-benzamide 50c. Yield: 66%; 
1
H-NMR  (300 MHz; CDCl3): 8.36 
(1H, s), 8.12 (1H, d), 7.88 (1H, d), 7.61 (2H, d), 7.41 
(1H, t), 7.21-7.14 (3H, m), 6.57 (1H, s), 5.15 (1H, d), 
4.85 (1H, d), 3.75-3.72 (1H, m), 3.66-3.63 (1H, m), 
3.53 (2H, t), 3.38 (3H, s); ES-MS calcd. for 
C21H21BrNO5: [M+H]
+
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N-Benzyl-3-[4-bromo-2-(2-methoxy-ethoxymethoxy)-5-oxo-2,5-dihydro-
furan-3-yl]-benzamide 50d. Yield: 63%; 
1
H-NMR  (300 MHz; CDCl3): 8.21 
(1H, s), 8.06 (1H, d), 7.81 (1H, d), 7.45 (1H, t), 
7.52-7.32 (5H, m), 6.54 (1H, s), 5.15 (1H, d), 4.85 
(1H, d), 4.58 (2H, d), 3.75-3.72 (1H, m), 3.66-3.63 
(1H, m), 3.53 (2H, t), 3.38 (3H, s); ES-MS calcd. 
for C22H23BrNO6: [M+H]
+
 476.06 and 478.06 (1:1); 
found 476.1 and 478.1 (1:1). 
3-Bromo-5-(2-methoxy-ethoxymethoxy)-4-[3-(piperidine-1-carbonyl)-
phenyl]-5H-furan-2-one 50e. Yield: 72%; 
1
H-NMR  (300 MHz; CDCl3): 
8.05 (1H, d), 7.87 (1H, s), 7.55 (1H, d), 7.48 (1H, t), 
6.58 (1H, s), 5.18 (1H, d), 4.87 (1H, d), 3.79-3.73 (1H, 
m), 3.68-3.58 (5H, m), 3.41 (3H, s), 3.36 (2H, t), 1.71 
(4H, quint), 1.55 (2H, quint); ES-MS calcd. for 
C20H25BrNO6: [M+H]+ 454.08 and 456.08 (1:1); found 
454.0 and 456.0 (1:1). 
 
6.2.7. MEM-cleavage: general procedure 
The MEM-protected intermediates 49a-f, 50a-e and 35a-d were dissolved in a 
solution of TFA/TIS/H2O 95:2.5:2.5. The mixture was stirred at room 
temperature for 1.5 h and concentrated in vacuo to leave dark oil purified by 
flash chromatography (100% n-hexane to 30% diethyl ether/n-hexane). All the 
products 27a-d, 41a-f and 42a-e were obtained as white solids.  
3-Bromo-5-hydroxy-4-(1H-indol-2-yl)-5H-furan-2-one 27a. Yield: 90%; 
1
H-NMR δ (300 MHz; CDCl3): 9.25 (1H, s), 7.72 (1H, d, 
J=7.0 Hz), 7.46 (2H, m), 7.38 (1H, t), 7.20 (1H, d, J=8.3 Hz), 
6.48 (1H, s); 
13
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139.6, 135.5, 134.8, 129.1, 124.0, 124.4, 124.3, 122.9, 112.0, 98.1; ES-MS 
calcd. for C12H7BrNO3: [M-H]
-
 293.97 and 291.97 (1:1); found 293.8 and 
291.8 (1:1). 
4-Benzofuran-2-yl-3-bromo-5-hydroxy-5H-furan-2-one 27b. Yield: 88%; 
1
H-NMR δ (300 MHz; CDCl3): 7.74 (1H, s), 7.73 (1H, d, 
J=7.8 Hz), 7.59 (1H, d, J=8.2 Hz), 7.47 (1H, t), 7.35 (1H, t), 
6.55 (1H, s); 
13
C-NMR δ (75 MHz; CDCl3): 166.8, 151.1, 
141.2, 137.0, 135.8, 130.8, 126.2, 125.8, 124.6, 124.1, 113.2, 
99.1; ES-MS calcd. for C12H6BrO4: [M-H]
-
 294.95 and 292.95 
(1:1); found 294.9 and 292.9 (1:1). 
3-Bromo-5-hydroxy-4-styryl-5H-furan-2-one 27c. Yield: 89%; 
1
H-NMR δ 
(300 MHz; CDCl3): 7.59 (3H, m), 7.42 (2H, d, J=8.3 Hz), 7.38 
(1H, d, J=16.4 Hz), 6.98 (1H, d, J=16.4 Hz), 6.34 (1H, s); 
13
C-
NMR δ (75 MHz; CDCl3): 166.3, 156.3, 136.2, 130.5, 130.4, 
130.2, 129.7, 128.2, 128.1, 127.1, 107.1, 103.8; ES-MS calcd. 
for C12H8BrO3: [M-H]
-
 280.97 and 278.97 (1:1); found 280.8 




H-NMR δ (300 MHz; CDCl3): 7.58 (2H, 
d, J=8.2 Hz), 7.36 (1H, d, J=16.2 Hz), 7.11 (2H, d, 
J=8.2 Hz), 6.90 (1H, d, J=16.2 Hz), 6.34 (1H, s); 
13
C-
NMR δ (75 MHz; CDCl3): 166.5, 163.5, 103.8, 156.7, 
107.6, 127.9, 130.8, 132.5, 130.1, 117.1; ES-MS calcd. 
for C12H7BrFO3: [M-H]
-
 298.96 and 296.96 (1:1); found 298.9 and 296.9 
(1:1). 
3-Bromo-5-hydroxy-4-[4-(pyrrolidine-1-carbonyl)-phenyl]-5H-furan-2-
one 41a. Yield: 92%; 
1
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7.49 (2H, d, J=8.2), 6.32 (1H, s), 3.60 (2H, t), 3.35 (2H, 
t), 1.95 (2H, quint), 1.85 (2H, quint); 
13
C-NMR δ (125 
MHz; CDCl3): 168.2, 165.1, 154.0, 140.4, 134.8, 129.1, 
128.6, 110.0, 99.6, 45.2, 28.3.
 
ES-MS calcd. for 
C15H15BrNO4: [M+H]
+
 352.01 and 354.01 (1:1); found 
352.2 and 354.2 (1:1). 
3-Bromo-5-hydroxy-4-[4-(morpholine-4-carbonyl)-phenyl]-5H-furan-2-
one 41b. Yield: 90%; 
1
H-NMR  (500 MHz; CDCl3): 8.02 (2H, d, J=7.8 Hz), 
7.49 (2H, d, J=8.2 Hz), 6.40 (1H, s), 3.79 (4H, m), 3.63 
(4H, m); 
13
C-NMR δ (125 MHz; CDCl3): 168.7, 166.1, 
154.1, 139.2, 135.3, 129.5, 128.9, 111.2, 99.1, 67.5, 
66.9. ES-MS calcd. for C15H15BrNO5: [M+H]
+
 368.01 
and 370.00 (1:1); found 368.2 and 470.2 (1:1). 
4-(4-Bromo-2-hydroxy-5-oxo-2,5-dihydro-furan-3-yl)-N-phenyl-
benzamide 41c. Yield: 89%; 
1
H-NMR  (500 MHz; CD3OD): 7.99 (2H, d, 
J=7.8 Hz), 7.54 (2H, d, J=8.2 Hz), 7.22 (2H, t), 6.92-
6.85 (3H, m), 6.57 (1H, s); 
13
C-NMR δ (125 MHz; 
CDCl3): 166.5, 164.2, 154.5, 139.8, 138.8, 137.8, 134.2, 
129.8, 128.5, 124.6, 121.1, 110.5, 98.9. ES-MS calcd. for 
C17H13BrNO4: [M+H]
+
 373.99 and 375.99 (1:1); found 
373.9 and 375.9 (1:1). 
N-Benzyl-4-(4-bromo-2-hydroxy-5-oxo-2,5-dihydro-furan-3-yl)-
benzamide 41d. Yield: 82%; 
1
H-NMR  (500 MHz; CDCl3): 8.01 (2H, d, 
J=7.8 Hz), 7.67 (1H, t), 7.88-7.77 (4H, m), 7.45 
(2H, d, J=8.2 Hz), 6.46 (1H, s), 4.67 (2H, d, J=7.2 
Hz);  
13
C-NMR δ (125 MHz; CDCl3): 168.4, 165.8, 

































- 108 - 
 
127.5, 126.2, 111.4, 99.7, 50.6. ES-MS calcd. for C18H15BrNO4: [M+H]
+
 
388.01 and 390.01 (1:1); found 388.1 and 390.1 (1:1). 
3-Bromo-5-hydroxy-4-[4-(piperidine-1-carbonyl)-phenyl]-5H-furan-2-one 
41e. Yield: 91%; 
1
H-NMR δ (500 MHz; CDCl3): 7.89 (2H, d, J=7.8 Hz), 7.31 
(2H, d, J=8.2 Hz), 6.24 (1H, s), 3.71 (2H, t), 3.31 (2H, 
t), 1.70 (4H, quint), 1.52 (2H, quint); NMR δ (125 
MHz; CDCl3): 168.5, 164.8, 153.7, 139.8, 134.5, 129.4, 
128.1, 111.1, 99.1, 45.4, 28.6, 26.7. ES-MS calcd. for 
C16H17BrNO4: [M+H]
+
 366.03 and 368.02 (1:1); found 366.0 and 368.0 (1:1). 
3-Bromo-5-hydroxy-4-[4-(piperazine-1-carbonyl)-phenyl]-5H-furan-2-one 
41f. Yield: 80%; 
1
H-NMR  (500 MHz; CDCl3): 7.95 (2H, d, J=7.8 Hz), 7.44 
(2H, d, J=8.2 Hz), 6.39 (1H, s), 3.81 (4H, m), 3.24 
(2H, t), 3.13 (2H, t); 
13
C-NMR δ (125 MHz; CDCl3): 
168.2, 165.8, 154.5, 139.6, 134.9, 129.1, 128.3, 
110.6, 99.7, 67.1, 66.2. ES-MS calcd. for 
C15H16BrN2O4: [M + H]
+
 367.02 and 369.02 (1:1); found 367.8 and 369.8 
(1:1). 
3-Bromo-5-hydroxy-4-[3-(pyrrolidine-1-carbonyl)-phenyl]-5H-furan-2-
one 42a. Yield: 90%; 1H-NMR δ (500 MHz; CDCl3): 8.07 (1H, d, J=7.8 Hz), 
8.04 (1H, s), 7.61 (1H, d, J=8.2 Hz), 7.49 (1H, t), 6.37 
(1H, s), 3.61 (2H, t), 3.47 (2H, t), 2.01 (2H, quint), 1.95 
(2H, quint); NMR δ (125 MHz; CDCl3): 167.6, 165.2, 
153.0, 134.7, 129.7, 129.1, 128.4, 127.7, 126.9, 109.0, 
98.9, 49.9, 46.7, 26.0, 23.9.
 
ES-MS calcd. for C15H15BrNO4: [M+H]
+
 352.01 
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3-Bromo-5-hydroxy-4-[3-(morpholine-4-carbonyl)-phenyl]-dihydro-
furan-2-one 42b. Yield: 87%; 
1
H-NMR δ (500 MHz; CDCl3): 8.06 (1H, d, 
J=7.8 Hz), 7.96 (1H, s), 7.57 (1H, t), 7.39 (1H, d, J=8.2 
Hz), 6.37 (1H, s), 3.83 (4H, m), 3.62 (4H, m); 
13
C-
NMR δ (125 MHz; CDCl3): 169.2, 166.3, 154.2, 135.0, 
130.7, 130.0, 129.6, 129.3, 127.9, 111.0, 99.5, 67.7, 
67.4. ES-MS calcd. for C15H15BrNO5: [M+H]
+
 368.01 and 370.00 (1:1); found 
368.2 and 370.2 (1:1). 
3-(4-Bromo-2-hydroxy-5-oxo-2,5-dihydro-furan-3-yl)-N-phenyl-
benzamide 42c. Yield: 86%; 
1
H-NMR  (500 MHz; CDCl3): 8.41 (1H, s), 
8.17 (1H, d, J=7.8 Hz), 7.92 (1H, d, J=8.2 Hz), 7.61 
(2H, d, J=8.2 Hz), 7.41 (1H, t), 7.23-7.16 (3H, m), 
6.56 (1H, s). 
13
C-NMR δ (125 MHz; CDCl3): 166.9, 
164.7, 154.3, 138.5, 134.8, 130.5, 129.6, 129.1, 
128.8, 128.2, 127.7, 124.5, 121.5, 109.9, 99.6. ES-MS calcd. for 
C17H13BrNO4: [M+H]
+
 373.99 and 375.99 (1:1); found 374.3 and 376.3 (1:1). 
N-Benzyl-3-(4-bromo-2-hydroxy-5-oxo-2,5-dihydro-furan-3-yl)-
benzamide 42d. Yield: 84%; 
1
H-NMR  (500 MHz; CDCl3): 8.33 (1H, s), 
8.13 (1H, d, J=7.8 Hz), 7.77 (1H, d, J=8.2 Hz), 7.53 
(1H, t), 7.42-7.27 (5H, m), 6.50 (1H, s), 4.58 (2H, 
d, J=8.3 Hz); 
13
C-NMR δ (125 MHz; CDCl3): 
168.2, 165.0, 154.3, 141.4, 139.3, 134.8, 129.5, 
128.8, 128.2, 127.6, 127.3, 126.3, 125.4, 110.5, 99.5, 50.4. ES-MS calcd. for 
C18H15BrNO4: [M+H]
+
 388.01 and 390.01 (1:1); found 388.2 and 390.2 (1:1). 
3-Bromo-5-hydroxy-4-[3-(piperidine-1-carbonyl)-phenyl]-5H-furan-2-one 
42e. Yield: 92%; 
1
H-NMR  (500 MHz; CDCl3): 8.01 (1H, d, J=7.8 Hz), 7.87 
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(2H, t), 1.70 (4H, quint), 1.55 (2H, quint); 
13
C-NMR δ 
(125 MHz; CDCl3): 168.7, 164.3, 153.3, 134.5, 130.2, 
129.6, 129.2, 128.8, 127.4, 110.6, 99.5, 45.7, 29.1, 
26.2. ES-MS calcd. for C16H17BrNO4: [M+H]
+
 366.03 
and 368.02 (1:1); found 366.0 and 368.0 (1:1). 
 
6.2.8. THP-cleavage: general procedure 
The THP-protected intermediates 31e-i and 32e-i were dissolved in a solution 
of TFA/TIS/H2O 95:2.5:2.5. The mixture was stirred at room temperature for 
1.5 h and concentrated in vacuo to leave white precipitate that was purified by 
flash chromatography (100% n-hexane to 30% diethyl ether/n-hexane). All the 
products 28e-i and 29e-i were obtained as white solids.  
4-Benzo[b]tiophen-2-yl-5-hydroxy-5H-furan-2-one 28e. Yield: 90%. 
1
H-
NMR δ (600 MHz, CDCl3): 7.87 (2H, d, J=7.7 Hz) 7.83 (1H, 
s), 7.48-7.42 (2H, m), 6.52 (1H, s), 6.29 (1H, s); 
13
C-NMR δ 
(150 MHz, CDCl3): 169.6, 156.4, 141.1, 139.3, 131.8, 128.0, 
127.6, 125.5, 125.2, 122.3, 114.9, 97.3; ES-MS calcd. for 
C12H7O3S: [M-H]
-
 231.01; found 231.0.  
5-Hydroxy-4-phenyl-5H-furan-2-one 28f. Yield: 89%. 
1
H-NMR δ (600 
MHz, CDCl3): 7.73-7.71 (2H, dd, J=2.5, 8.2 Hz), 7.52-7.48 
(3H, m), 6.55 (1H, s), 6.43 (1H, s); 
13
C-NMR δ (150 MHz, 
CDCl3): 171.1, 162.3, 131.9, 129.5, 129.4, 128.2, 116.0, 98.6; 
ES-MS calcd. for C10H7O3: [M-H]
-
 175.03; found 175.1.  
4-(2-Hydroxy-5-oxo-2,5-dihydro-furan-3-yl)-benzaldehyde 28g. Yield: 
93%.
1
H-NMR δ (600 MHz, CD3OD): 10.08 (1H, s), 7.99 
(2H, d, J=8.3 Hz), 7.88 (2H, d, J=8.3 Hz), 6.61 (1H, s), 6.54 
(1H, s); 
13
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162.2, 137.3, 135.9, 129.4, 128.5, 114.5, 97.8; ES-MS calcd. for C11H7O4: [M-
H]
-
 203.03; found 203.1.  
5-Hydroxy-4-(4-methoxy-phenyl)-5H-furan-2-one 28h. Yield: 91%. 
1
H-
NMR δ (600 MHz, CD3OD): 7.75 (2H, d, J=9.0 Hz), 7.02 
(2H, d, J=9.0 Hz), 6.52 (1H, s), 6.37 (1H, s), 3.86 (3H, s); 
13
C-NMR δ (150 MHz, CD3OD): 172.2, 163.8, 162.4, 129.3, 
121.9, 113.5, 111.0, 98.0, 54.4; ES-MS calcd. for C11H9O4: 
[M-H]
-
 205.05; found 205.0.  
5-Hydroxy-4-naphthalen-1-yl-5H-furan-2-one 28i. Yield: 88%. 
1
H-NMR δ 
(600 MHz, CD3OD): 8.18 (1H, d), 8.00-7.95 (2H, m), 7.70 
(1H, d), 7.63-7.54 (3H, m), 6.75 (1H, s), 6.48 (1H, s); 
13
C-
NMR δ (150 MHz, CD3OD): 169.8, 163.8, 133.5, 130.8, 
130.4, 128.9, 128.2, 127.6, 127.2, 126.9, 126.5, 124.4, 119.8, 
99.8; ES-MS calcd. for C14H9O3: [M-H]
-
 225.05; found 225.2.  
3-Benzo[b]thiophen-2-yl-5-hydroxy-5H-furan-2-one 29e. Yield: 91%. 
1
H-
NMR δ (600 MHz, CDCl3): 8.02 (1H, s), 7.86-7.81 (2H, m), 
7.41-7.38 (2H, m), 7.24 (1H, s), 6.28 (1H, s); 
13
C-NMR δ 
(150 MHz, CDCl3): 168.4, 142.5, 142.3, 139.9, 132.9, 130.1, 
127.8, 127.5, 126.7, 126.4, 122.7, 96.7; ES-MS calcd. For 
C12H7O3S: [M-H]
-
 231.01; found 231.0. 
5-Hydroxy-4-phenyl-5H-furan-2-one 29f. Yield: 89%. 
1
H-NMR δ (600 
MHz, CD3OD): 7.71-7.68 (2H, m), 7.48-7.44 (3H, m), 7.35 
(1H, s), 6.72 (1H, s); 
13
C-NMR δ (150 MHz, CD3OD): 168.6, 
139.5, 131.5, 131.3, 129.3, 128.1, 128.0, 97.0; ES-MS calcd. 
for C10H7O3: [M-H]
-




















H-NMR δ (600 MHz, CD3OD): 10.02 (1H, s), 8.12 
(2H, d, J=8.3 Hz), 7.97 (2H, d, J=8.3 Hz), 7.76 (1H, s), 6.22 
(1H, s); 
13
C-NMR δ (150 MHz, CD3OD): 191.9, 169.9, 
142.7, 136.8, 135.1, 132.4, 129.3, 127.7, 96.7; ES-MS 
calcd. for C11H7O4: [M-H]
-
 203.03; found 203.1.
 
5-Hydroxy-3-(4-methoxy-phenyl)-5H-furan-2-one 29h. Yield: 90%. 
1
H-
NMR δ (600 MHz, CD3OD): 7.86 (2H, d, J=9.0 Hz), 7.42 
(1H, s), 6.97 (2H, d, J=9.0 Hz), 6.15 (1H, s), 3.82 (1H, s); 
13
C-NMR δ (150 MHz, CD3OD): 170.5, 160.6, 142.0, 
132.5, 128.3, 121.2, 113.5, 96.3, 54.1; ES-MS calcd. for 
C11H9O4: [M-H]
-
 205.05; found 205.0. 
5-Hydroxy-3-naphthalen-1-yl-5H-furan-2-one 29i. Yield: 88%. 
1
H-NMR δ 
(600 MHz, CD3OD): 7.98-7.91 (3H, m), 7.59-7.52 (4H, 
m), 7.49 (1H, s), 6.36 (1H, s); 
13
C-NMR δ (150 MHz, 
CD3OD): 171.2, 149.2, 134.2, 132.4, 133.3, 131.1, 127.7, 
127.2, 126.3, 125.8, 125.4, 124.7, 124.4, 97.3; ES-MS 
calcd. for C14H9O3: [M-H]
-
 225.05; found 225.2.  
 
6.2.9. Synthesis of acetic acid 3-benzo[b]thiophen-2-yl-5-oxo-2,5-dihydro-
furan-2-yl ester 30 
Compound 28e was dissolved in dry DMF and, stirring the mixture at room 
temperature, acetic anhydride (5 equiv.) and DIPEA (5 equiv.) were added. 
After 2 h, the mixture was diluted with 10 mL of HCl 1 N and the aqueous 
phase was extracted with DCM (3 x 10 mL). The organics were dried over 
Na2SO4, filtered and concentrated in vacuo. Yield: 81%; 
1
H-NMR δ (300 
MHz, CDCl3): 7.86 (1H, d, J=7.8 Hz), 7.50 (1H, s), 7.44 (3H, m), 6.52 (1H, s), 
6.35 (1H, s), 2.23 (3H, s); 
13
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141.1, 139.3, 132.8, 128.6, 127.7, 125.4, 125.2, 122.3, 115.2, 
108.5, 22.1; ES-MS calcd. for C14H9O4S: [M-H]
-
 273.03; 
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7.1. General methods 
All water and air sensitive reactions were carried out under an inert 
atmosphere (Ar or N2) in oven- or flame-dried glassware. All the chemicals, 
commercially available, were used as received. DCM and THF were distilled 
from CaH2 immediately prior to use. Water was degassed under vacuum (10 
mbar). 
Microwave reactions were performed on a CEM Discover® single mode 
platform using 10 mL pressurized vials.  
Reactions were monitored on silica gel 60 F254 (Merck) plates and visualized 
with potassium permanganate or cerium sulfate and under UV (λ=254 nm, 365 
nm). Flash column chromatography was performed using Merck 60/230-400 
mesh silica gel. Analytical and semipreparative reverse-phase HPLC 
purifications were performed on a Waters instrument using Jupiter C-18 
column (250 x 4.60 mm, 5 µm, 300 Å; 250 x 10.00 mm, 10 µm, 300 Å, 
respectively).  




H, HMBC, HSQC) and carbon detected NMR spectra were 
recorded on Bruker instruments of Avance series operating at 300, 500 and 
600 MHz and 75, 125 and 150 MHz, respectively. Chemical shifts are 
expressed in parts per million (ppm) on the delta (δ) scale. The solvent peak 
was used as internal reference: for 
1
H NMR CDCl3 = 7.26 ppm, CD3OD = 
3.34 ppm; for 
13
C NMR: CDCl3 = 77.0 ppm, CD3OD = 47.7 ppm. 
Multiplicities are reported as follows: s, singlet; d, doublet; t, triplet; quint, 
quintuplet; m, multiplet; dd, doublet of doublets.  
Electrospray mass spectrometry (ES-MS) was performed on a LCQ DECA 
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7.2. Methods and materials 
7.2.1. Esterification of boronic acids 43 and 94 
The boronic acids 43 and 94 (0.667 mmol) were dissolved in 6 mL of ethyl 
acetate and, stirring the solution, pinacol (0.667 mmol) was added. After 4h 
the reaction was stopped adding anhydrous Na2SO4 (1 g) and CaCl2 (1 g). The 
mixture was filtered and concentrated in vacuo (Yield: 91% of 45 and 89% of 
95). 
  
7.2.2. Synthesis of 4-[2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-
2-yl)-benzyl]-morpholine n 
Under inert atmosphere (N2), 1 equiv. of boronic ester 95 was dissolved in 
anhydrous CH3OH (1 mL/0.18 mmol of ester). The mixture was kept under 
stirring at room temperature; anhydrous amine 96 (4 equiv.), ZnCl2 (0.5 
equiv.) and NaCNBH3 (1 equiv.) were added. After 4 h, when the reagents 
disappeared, the reaction was stopped and 10 mL of an aqueous solution of 
NaOH 0.1 M was added. After concentration of CH3OH in vacuo, the aqueous 
phase was extracted with ethyl acetate (3 x 10 mL) and the organics were 
dried over Na2SO4, filtered and concentrated in vacuo. The obtained oil was 
purified on silica gel by flash chromatography (100% n-hexane to 50% ethyl 
acetate/n-hexane). Yield: 75%: 
1
H NMR δ (300 MHz; 
CDCl3): 7.98 (1H, d), 7.78 (1H, s), 7.24 (1H, d), 4.53 
(2H, s), 4.10 (2H, t), 3.93 (3H, s), 3.76 (2H, t), 3.47 
(4H, m), 1.35 (12H, s); ES-MS calcd. for C18H29BNO4: [M+H]
+
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7.2.3. Synthesis of morpholin-4-yl-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxa-
borolan-2-yl)-phenyl]-methanone j 
The pinacol ester 45 (1 equiv.) and morpholine 96 (2 equiv.) were dissolved in 
DMF. TEA, HOBt and DIC (2 equiv. of each one) were added. The mixture 
was leaved at room temperature for 48 hours under stirring. When TLC 
showed the consumption of the pinacol ester 45, the reaction was stopped 
adding HCl 1N (10 mL). The aqueous phase was extracted with ethyl acetate 
(3 x 10 mL) and the organic phase was washed firstly with a saturate solution 
of NaHCO3 and then with brine. The organics were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude was purified by flash 
chromatography (10% diethyl ether/n-hexane to 50% diethyl ether/n-hexane) 
with yield: 85%. 
1
H NMR δ (300 MHz; CDCl3): 7.99 (1H, s), 7.83 (1H, d), 
7.45 (1H, d), 7.37 (1H, t), 3.85 (2H, t), 3.70 (4H, m), 
3.52 (2H, t), 1.34 (12H, s). ES-MS calcd. for 
C17H25BNO4: [M+H]
+
 318.18; found 318.3. 
 
7.2.4. Synthesis of 1,4-disubstituted 1,2,3-triazoles 80-81: general procedure 
Propargyl alcohol 78 or 1-bromo-4-ethynylbenzene 79 (1 mmol) and 
azidomethyl phenyl sulfide 77 (1.2 mmol) were suspended in a 1:1 mixture of 
water and t-BuOH (1.5 mL each). Sodium ascorbate (100 µL of freshly 
prepared 1 M solution in water) was added, followed by Cu(II) sulfate 
pentahydrate (100 µL of a 0.1 M solution in water). The heterogeneous 
mixture was vigorously stirred overnight at room temperature. When TLC 
analysis indicated complete consumption of the reactants, the reaction mixture 
was diluted with 50 mL of water and cooled in ice; the white precipitate was 
collected by filtration. After being washed with cold water (20 mL), the 










- 120 - 
 
(1-phenylsulfanylmethyl-1H-[1,2,3]triazol-4-yl)-methanol 80. Yield: 89%; 
1
H-NMR δ (300 MHz; CDCl3): 7.55 (1H, s), 7.28-7.22 
(5H, m), 5.55 (2H, s), 4.63 (2H, s); ES-MS calcd. for 
C10H12N3OS: [M+H]
+
 222.06; found 222.2. 
4-(4-bromo-phenyl)-1-phenylsulfanylmethyl-1H-[1,2,3]triazole 81. Yield: 
93%; 
1
H-NMR δ (300 MHz; CDCl3): 7.76 (1H, s), 
7.64 (2H, d), 7.53 (2H, d), 7.40-7,28 (5H, m), 5.65 
(2H, s); HRMS calcd. for C15H13BrN3S: [M+H]
+
 
345.99 and 347.99 (1:1); found 345.8 and 347.8 (1:1). 
 
7.2.5. Synthesis of triazoles 85-87 from halides 82-84: general procedure 
The appropriate halide 82-84 (1.1 mmol), 1-bromo-4-ethynylbenzene 79 (1.0 
mmol) and sodium azide (1.3 mmol) were suspended in a 1:1 mixture of water 
and t-BuOH (1.5 mL each) in a 10 mL crimp-sealed thick-walled glass tube 
equipped with a small magnetic stirring bar. Copper wire (0.80 mmol) and 
copper sulphate solution (1N, 200 μL) were added to the mixture. Then the 
mixture was irradiated for 30 minutes setting the power at 200 W, the 
temperature at 120 °C, the pressure at 250 psi and the Power Max ON. After 
completion of the reaction, the vial was cooled to 50 °C by gas jet cooling 
before it was opened. The mixture was then diluted with water (20 mL) and 
filtered. The residue was washed with cold water (20 mL), 0.25 N HCl (20 
mL) and finally with petroleum ether (20 mL) to furnish the desired triazoles 
85-87. 
4-(4-Bromo-phenyl)-1-(2-o-tolyl-ethyl)-1H-[1,2,3]triazole 85. Yield: 77%; 
1
H-NMR δ (300 MHz; CDCl3): 7.63 (2H, d), 7.52 
(2H, d), 7.38 (1H, s), 7.17-7.12 (4H, m), 4.60 (2H, 
t), 3.23 (2H, t), 2.25 (3H, s); HRMS calcd. for 
C17H17BrN3: [M+H]
+
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4-(4-Bromo-phenyl)-1-(3-phenyl-propyl)-1H-[1,2,3]triazole 86. Yield: 
79%; 
1
H-NMR δ (300 MHz; CDCl3): 7.71-7.68 
(3H, m), 7.55 (2H, d), 7.31-7.17 (5H, m), 4.40 
(2H, t), 2.70 (2H, t), 2.30 (2H, quint); HRMS calcd. for C17H17BrN3: [M+H]
+
 
342.05 and 344.05 (1:1); found 342.0 and 344.0 (1:1). 
4-[4-(4-Bromo-phenyl)-[1,2,3]triazol-1-ylmethyl]-3-nitro-benzoic acid 87. 
Yield: 73%; 
1
H-NMR δ (300 MHz; CD3OD): 
8.72 (1H, s), 8.35 (1H, s), 8.24 (1H, d), 7.70 
(2H, d), 7.56 (2H, d), 7.18 (1H, d), 6.08 (2H, 
s); HRMS calcd. for C16H12BrN4O4: [M+H]
+
 403.00 and 404.99 (1:1); found 
403.3 and 405.3 (1:1). 
 
7.2.6. Synthesis of 4-[4-(4-bromo-phenyl)-[1,2,3]triazole-1-sulfonyl]-benzoic 
acid 89 
1-Bromo-4-ethynylbenzene 79 (0.60 mmol) and 4-carboxybenzene-
sulfonazide 88 (0.50 mmol) were dissolved in 1.00 mL of dry chloroform. 2,6-
lutidine (0.60 mmol) and CuI (0.05 mmol) were added and the solution was 
stirred for 12 h at 0°C under inert atmosphere of nitrogen. When TLC analysis 
indicated complete consumption of the reactants, the reaction mixture was 
diluted with 10 mL of water. The aqueous layer was extracted with ethyl 
acetate (3 x 10 mL). The organics were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude was purified by flash chromatography (10% 
diethyl ether/n-hexane to 80% diethyl ether/n-hexane) and furnished 57% of 
pure desired triazole 89 as a white powder.
1
H-NMR δ (300 MHz; CD3OD): 
8.48 (1H, s), 8.23-8.16 (4H, m), 7.66 (2H, d), 
7.53 (2H, d); HRMS calcd. for C15H11BrN3O4S: 
[M+H]
+
 407.96 and 409.96 (1:1); found 407.8 
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7.2.7. Synthesis of 4-benzyl-5-iodo-1-phenylsulfanylmethyl-1H-
[1,2,3]triazole 91 
3-Phenyl-1-propyne 90 (1.0 mmol) and azidomethyl phenyl sulfide 77 (1.1 
mmol) were suspended in THF (30 mL). DIPEA (1.1 mmol), NBS (1.1 mmol) 
and CuI (1.1 mmol) were successively added. The mixture was stirred at room 
temperature for 4 h. After removal of the solvent, the crude product was 
dissolved in ethyl acetate (5 mL) and diluted with water (10 mL). The aqueous 
layer was extracted with ethyl acetate (3 x 10 mL). The organics were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude was purified by 
flash chromatography (5% diethyl ether/n-hexane to 15% diethyl ether/n-
hexane) to give compound 91. Yield: 51%: 
1
H NMR δ 
(300 MHz; CDCl3): δ 7.32-7.21 (10H, m), 5.60 (2H, s), 
4.03 (2H, s); HRMS calcd. for C16H15IN3S: [M+H]
+
 
408.00; found 408.2. 
 
7.2.8. Suzuki coupling: general procedure 
In a CEM Discover® vial, each of the intermediate 81, 85-87, 89 or 91 (1 
equiv), the appropriate boronic acid a-i or 92 (1.5 equiv.), Pd(dppf)Cl2 (0.05 
equiv.) and CsF (4 equiv.) were placed. Water (500 µL) and THF (500 µL) 
were added under argon atmosphere. The mixture was irradiated for 20-30 
minutes, setting the power at 200 W, the temperature at 120 °C, the pressure at 
250 psi and the Power Max ON. At completion of the reaction, the vial was 
cooled to 50 °C by gas jet cooling before it was opened. After diluting with 10 
mL of aqueous solution of HCl 1 N, the aqueous layer was extracted with 
ethyl acetate (3 x 10 mL). The organics were then dried over Na2SO4, filtered 
and concentrated in vacuo. The crude was purified by flash chromatography 
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4-(4-Biphenyl-4-yl-[1,2,3]triazol-1-ylmethyl)-3-nitro-benzoic acid 54. 
Yield: 84%; 
1
H-NMR δ (500 MHz; CD3OD): 
8.77 (1H, s), 8.63 (1H, s), 8.04 (1H, d, J=8.11 
Hz), 7.89 (1H, d, J=7.89 Hz), 7.73 (2H, d, J=7.89 
Hz), 7.61 (2H, d, J=7.23 Hz), 7.38 (2H, d, J=8.11 Hz), 7.25 (2H, t), 7.05 (1H, 
t), 6.22 (2H, s); 
13
C-NMR δ (125 MHz; CD3OD): 165.5, 147.0, 146.1, 139.5, 
138.4, 134.3, 133.0, 130.1, 129.4, 128.0, 126.9, 126.2, 125.7, 125.4, 125.1, 
124.8, 121.9, 49.8. ES-MS calcd. for C22H17N4O4: [M+H]
+
 401.12; found 
401.3. 
4'-(1-Phenylsulfanylmethyl-1H-[1,2,3]triazol-4-yl)-biphenyl-4-ol 56. Yield: 
52%; 
1
H-NMR δ (300 MHz; CDCl3): 7.84 (1H, 
s), 7.80 (2H, d, J=6.36 Hz), 7.58 (2H, d, J=7.89 
Hz), 7.50 (2H, d, J=8.11 Hz), 7.35-7.29 (5H, 
m), 6.90 (2H, d, J=8.55 Hz), 5.67 (2H, s); 
13
C-
NMR δ (75 MHz; CDCl3): 155.4, 155.1, 146.0, 140.1, 139.2, 130.4, 128.9, 
127.5, 126.1, 124.4, 117.9, 116.8, 113.6, 112.8, 52.6. ES-MS calcd. for 
C21H18N3OS: [M+H]
+
 360.11; found 360.4. 
4'-(1-Phenylsulfanylmethyl-1H-[1,2,3]triazol-4-yl)-biphenyl-3-ol 57. Yield: 
47%; 
1
H-NMR δ (600 MHz; CD3OD): 7.95 
(1H, s), 7.79 (2H, d, J=8.77 Hz), 7.63 (2H, d, 
J=8.33 Hz), 7.39-7.35 (5H, m), 7.26 (1H, t), 
7.10 (1H, d, J=7.89 Hz), 7.08 (1H, t), 6.81 (1H, 
dd, J=2.63, 8.33 Hz), 5.71 (2H, s); 
13
C-NMR δ (150 MHz; CD3OD): 155.9, 
155.7, 146.4, 140.3, 139.6, 131.4, 130.7, 128.0, 127.9, 126.2, 124.7, 118.3, 
117.2, 117.0, 113.3, 112.5, 52.9. ES-MS calcd. for C21H18N3OS: [M+H]
+
 






















H-NMR δ (300 MHz; CDCl3): 
8.26 (1H, dd, J=2.55, 8.11 Hz), 7.97-7.88 (7H, 
m), 7.78 (1H, s), 7.70-7.50 (8H, m), 7.31-7.28 
(2H, d, J=6.80 Hz), 4.45 (2H, t), 2.92 (2H, t), 
2.82 (2H, quint); 
13
C-NMR δ (75 MHz; CDCl3): 146.3, 137.4, 134.3, 134.0, 
130.5, 130.1, 129.8, 129.5, 129.2, 129.0, 128.5, 127.9, 127.6, 126.8, 126.6, 
126.4, 126.1, 125.9, 125.7, 125.4, 125.1, 124.1, 123.6, 121.5, 52.0, 30.3, 20.5. 
ES-MS calcd. for C31H26N3: [M+H]
+
 440.20; found 440.4. 
4'-[1-(3-Phenyl-propyl)-1H-[1,2,3]triazol-4-yl]-biphenyl-4-ol 64. Yield: 
50%; 
1
H-NMR δ (300 MHz; CDCl3): 7.85 
(2H, d, J=7.67 Hz), 7.73 (1H, s), 7.60 (2H, d, 
J=7.45 Hz), 7.51 (2H, d, J=8.11 Hz), 7.30-
7.24 (5H, m), 6.90 (2H, d, J=8.33 z), 4.40 
(2H, t), 2.69 (2H, t), 2.30 (2H, quint); 
13
C-NMR δ (75 MHz; CDCl3): 153.1, 
148.5, 141.2, 139.6, 137.4, 128.9, 128.3, 127.8, 127.3, 126.5, 126.1, 125.5, 





[1,2,3]triazole 65.  Yield: 67%; 
1
H-NMR δ (300 MHz; CD3OD): 8.25 (1H, d, 
J=6.80 Hz), 7.73 (4H, m), 7.48-7.12 (12H, m), 
7.21 (1H, s), 7.15 (2H, m), 6.68 (1H, d, J=7.67 
Hz), 5.09 (2H, s), 4.35 (2H, t), 2.64 (2H, t), 2.25 
(2H, quint);
 13
C-NMR δ (75 MHz; CD3OD): 
155.3, 148.4, 141.4, 141.3, 134.3, 133.3, 131.3, 129.8, 129.7, 129.5, 129.1, 
128.7, 128.3, 127.6, 127.0, 126.9, 126.5, 126.1, 125.9, 125.3, 125.1, 121.6, 
121.1, 120.8, 119.5, 105.8, 71.1, 50.9, 33.1, 31.6. ES-MS calcd. for 
C34H30N3O: [M+H]
+
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4-[2'-(2-Chloro-5-trifluoromethyl-phenoxymethyl)-biphenyl-4-yl]-1-(3-
phenyl-propyl)-1H-[1,2,3]triazole 67. Yield: 72%; 
1
H-NMR δ (600 MHz; 
CDCl3): 7.90 (2H, d, J=8.11 Hz), 7.77 (1H, s), 
7.57 (1H, t), 7.49-7.44 (5H, m), 7.32 (1H, t), 
7.28-7.18 (5H, m), 7.14 (1H, d, J=8.11 Hz), 6.96 
(1H, s), 5.08 (2H, s), 4.43 (2H, t), 2.72 (2H, t), 
2.33 (2H, quint); 
13
C-NMR δ (150 MHz; CDCl3): 155.6, 148.3, 141.5, 141.3, 
134.0, 131.7, 129.8, 129.7, 129.2, 129.1, 128.9, 128.7, 128.4, 127.6, 127.2, 
126.7, 126.4, 126.1, 125.6, 123.9, 121.1, 118.4, 110.6, 69.8, 50.6, 31.8, 33.9. 
ES-MS calcd. for C31H26ClF3N3O: [M+H]
+
 548.16; found 548.6. 
4-[2'-(2-Chloro-5-trifluoromethyl-phenoxymethyl)-biphenyl-4-yl]-1-(2-o-
tolyl-ethyl)-1H-[1,2,3]triazole 68. Yield: 70%; 
1
H-NMR δ (300 MHz; 
CDCl3): 7.82 (2H, d, J=8.11 Hz), 7.57 (1H, d, 
J=5.48 Hz), 7.49-7.37 (6H, m), 7.18-7.12 (6H, 
m), 6.95 (1H, s), 5.07 (2H, s), 4.62 (2H, t), 3.27 
(2H, t), 2.27 (3H, s); 
13
C-NMR δ (75 MHz; 
CDCl3): 155.9, 148.1, 141.7, 135.6, 135.5, 134.3, 131.5, 130.1, 129.8, 129.7, 
129.5, 129.4, 129.3, 128.7, 128.2, 126.9, 126.5, 126.3, 126.1, 125.6, 125.5, 
123.5, 121.0, 118.2, 110.5, 69.6, 50.3, 33.5, 18.0. ES-MS calcd. for 
C31H26ClF3N3O: [M+H]
+
 548.16; found 548.3. 
4-{4-[2'-(Naphthalen-1-yloxymethyl)-biphenyl-4-yl]-1,2,3]triazole-1-
sulfonyl}-benzoic acid 70. Yield: 32%; 
1
H-NMR δ (500 MHz; CD3OD): 8.25 
(1H, d, J=7.67 Hz), 7.96 (1H, s), 7.83-
7.78 (4H, m), 7.55-7.40 (12H, m), 7.31 
(1H, t), 6.72 (1H, d, J=7.67 Hz), 5.14 
(2H, s); 
13
C-NMR δ (125 MHz; 
CD3OD): 172.4, 155.5, 149.1, 143.9, 142.0, 135.4, 134.9, 133.4, 132.1, 131.9, 
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125.4, 125.0, 123.1, 121.3, 120.6, 105.9, 71.7.
 
ES-MS calcd. for C32H24N3O5S: 
[M+H]
+
 562.14; found 562.5. 
5-Dimethylamino-naphthalene-1-sulfonic acid {4'-[1-(3-phenyl-propyl)-
1H-[1,2,3]triazol-4-yl]-biphenyl-4-yl}-amide 71. Yield: 38%; 
1
H-NMR δ 
(300 MHz; CD3OD): 8.50 (2H, dd, 
J=5.92, 8.77 Hz), 8.32 (1H, s), 8.25 
(1H, d, J=7.23 Hz), 7.82 (2H, d, J=8.33 
Hz), 7.65 (1H, t), 7.54 (1H, t), 7.43-7.37 
(4H, m), 7.28-7.17 (7H, m), 7.02 (1H, d, J=8.33 Hz), 4.46 (2H, t), 2.88 (6H, 
s), 2.68 (2H, t), 2.29 (2H, quint);
 13
C-NMR δ (75 MHz; CD3OD): 148.3, 141.5, 
140.1, 139.8, 137.9, 136.5, 134.2, 131.0, 130.1, 129.5, 129.3, 129.0, 128.5, 
128.3, 127.2, 126.5, 126.3, 126.0, 125.6, 125.1, 124.6, 124.4, 123.2, 122.2, 





[1,2,3]triazole 72. Yield: 52%; 
1
H-NMR δ (300 MHz; CD3OD): 8.21 (1H, d, 
J=7.67 Hz), 7.80-7.75 (3H, m), 7.68 (2H, d, 
J=8.11 Hz), 7.51-7.40 (8H, m), 7.31 (1H, d, 
J=7.45 Hz), 7.16-7.09 (3H, m), 7.04 (1H, d, 
J=6.80 Hz), 6.71 (1H, d, J=7.67 Hz), 5.12 (2H, 
s), 4.61 (2H, t), 3.26 (2H, t), 2.25 (3H, s); 
13
C-NMR δ (75 MHz; CD3OD): 
155.2, 148.6, 141.3, 135.2, 134.6, 133.9, 130.9, 130.7, 129.8, 129.6, 129.3, 
129.2, 129.1, 128.9, 127.4, 126.9, 126.5, 126.3, 126.1, 125.9, 125.7, 125.5, 
125.1, 125.0, 121.6, 121.1, 120.6, 105.6, 71.2, 50.9, 32.8, 18.1. ES-MS calcd. 
for C34H30N3O: [M+H]
+
 496.23; found 496.1. 
4-(5-Benzyl-3-phenylsulfanylmethyl-3H-[1,2,3]triazol-4-yl)-benzaldehyde 
73. Yield: 94%; 
1
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J=7.67 Hz), 7.26-7.17 (10H, m), 7.08 (2H, d, J=6.80 
Hz), 5.52 (2H, s), 3.98 (2H, s); 
13
C-NMR δ (75 MHz; 
CDCl3): 190.5, 155.9, 142.6, 141.2, 138.0, 136.9, 
133.6, 130.6, 129.5, 128.0, 127.0, 125.1, 117.5, 113.7, 
112.8, 53.3, 29.7. ES-MS calcd. for C23H20N3OS: [M+H]
+





H-NMR δ (500 MHz; CD3OD): 
8.13 (1H, s), 7.86 (2H, d, J=8.33 Hz), 7.75 
(2H, d, J=8.33 Hz), 7.71 (2H, d, J=8.33 Hz), 
7.28 (2H, d, J=8.33 Hz), 7.16-7.00 (4H, m), 
4.71 (2H, t), 3.32 (2H, t), 2.33 (3H, s). 
13
C-NMR δ (125 MHz; CD3OD): 
146.9, 139.9, 137.6, 135.9, 135.5, 130.3, 129.8, 129.4, 128.3, 127.6, 126.7, 
126.1, 125.8, 125.5, 121.4, 120.2, 50.5, 33.6, 18.9; ES-MS calcd. for 
C23H23N4: [M+H]
+




H-NMR δ (300 MHz; CDCl3): 
8.87 (2H, d, J=8.11 Hz), 7.73 (1H, s), 7.65 
(2H, d, J=8.11 Hz), 7.60 (2H, d, J=8.33 Hz), 
7.35-7.27 (7H, m), 7.11-7.07 (5H, m), 4.41 
(2H, t), 2.69 (2H, t), 2.31 (2H, quint); 
13
C-NMR δ (75 MHz; CDCl3): 155.8, 
155.1, 148.5, 141.7, 141.4, 135.5, 129.5, 128.7, 128.6, 127.3, 126.9, 126.7, 
126.5, 125.6, 121.4, 121.1, 120.4, 116.8, 50.5, 33.5, 31.4. ES-MS calcd. for 
C29H26N3O: [M+H]
+
 432.20; found 432.4. 
4-[4-(4'-Hydroxy-biphenyl-4-yl)-[1,2,3]triazol-1-ylmethyl]-3-nitro-benzoic 
acid 93b. Yield: 47%; 
1
H-NMR δ (300 MHz; CD3OD): 8.75 (1H, s), 8.53 (1H, 
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7.49 (2H, d, J=7.23 Hz), 7.24 (1H, d, J=8.11 
Hz), 6.81 (2H, d, J=8.35 Hz), 6.19 (2H, s); 
13
C-NMR δ (75 MHz; CD3OD): 165.1, 
157.3, 148.1, 141.3, 135.0, 134.2, 133.2, 131.7, 130.2, 128.2, 127.8, 127.1, 
126.6, 126.0, 125.9, 122.1, 115.5, 50.8. ES-MS calcd. for C22H17N4O5: 
[M+H]
+
 417.11; found 417.1. 
4-[4-(3'-Hydroxy-biphenyl-4-yl)-[1,2,3]triazol-1-ylmethyl]-3-nitro-benzoic 
acid 93c. Yield: 42%; 
1
H-NMR δ (300 MHz; CD3OD): 8.76 (1H, s), 8.23 (1H, 
d, J=8.09 Hz) 8.12 (1H, s), 7.83 (2H, d, 
J=8.11 Hz), 7.62 (2H, d, J=7.89 Hz), 7.41 
(1H, s), 7.23 (1H, t), 6.77-6.72 (3H, m), 6.05 
(2H, s); 
13
C-NMR δ (75 MHz; CD3OD): 165.7, 155.5, 147.5, 142.2, 141.4, 
135.1, 131.7, 130.5, 129.2, 128.6, 128.1, 127.1, 126.8, 125.6, 125.7, 122.6, 





acid 93d. Yield: 49%; 
1
H-NMR δ (300 MHz; CD3OD): 8.77 (1H, s), 8.53 (1H, 
s), 8.26 (1H, d, J=8.09 Hz), 7.88 (2H, d, 
J=7.89 Hz), 7.70 (2H, d, J=7.89 Hz), 7.49 
(2H, d, J=7.23 Hz), 7.24 (1H, d, J=8.11 Hz), 
6.81 (2H, d, J=8.35 Hz), 6.22 (2H, s); 
13
C-NMR δ (75 MHz; CD3OD): 165.4, 
157.1, 147.9, 140.8, 134.8, 134.6, 133.5, 131.3, 129.7, 128.6, 127.3, 126.8, 
126.1, 125.8, 125.4, 121.8, 115.8, 50.5. ES-MS calcd. for C22H18N5O4: 
[M+H]
+
 416.13; found 416.1. 
4-{4-[2'-(2-Chloro-5-trifluoromethyl-phenoxymethyl)-biphenyl-4-yl]-
[1,2,3]triazol-1-ylmethyl}-3-nitro-benzoic acid 93h. Yield: 62%; 
1
H-NMR δ 
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(2H, d, J=8.09 Hz), 7.65 (1H, d, J=5.48 Hz), 
7.50 (2H, d, J=8.11 Hz), 7.45-7.37 (6H, m), 
7.18 (1H, d, J=5.48 Hz), 6.18 (2H, s), 5.15 (2H, 
s); 
13
C-NMR δ (75 MHz; CDCl3): 165.6, 155.6, 
148.1, 141.2, 135.6, 135.2, 134.3, 131.7, 130.1, 129.9, 129.7, 129.5, 129.4, 
129.1, 128.5, 128.2, 126.8, 126.5, 126.3, 126.1, 125.6, 125.5, 123.5, 121.0, 





[1,2,3]triazol-1-ylmethyl}-3-nitro-benzoic acid 93i. Yield: 51%; 
1
H-NMR δ 
(300 MHz; CD3OD): 8.77 (1H, s), 
8.55 (1H, s), 8.24 (2H, d, J=8.09 
Hz), 7.89 (1H, d, J=7.89 Hz), 7.71 
(2H, d, J=7.89 Hz), 7.55 (2H, d, 
J=7.23 Hz), 7.50-7.46 (3H, m), 7.32 (2H, d, J=8.11 Hz), 7.13-7.09 (8H, m), 
6.95 (1H, d, J=8.09 Hz), 6.85 (1H, d, J=8.11 Hz), 6.19 (2H, s);
13
C-NMR δ (75 
MHz; CD3OD): 165.7, 156.9, 149.5, 149.1, 145.5, 140.5, 138.1, 136.6, 136.1, 
135.4, 134.2, 133.2, 131.5, 130.3, 129.8, 128.5, 128.2, 128.0, 127.8, 127.3, 
126.4, 126.0, 125.2, 123.5, 118.0, 115.3, 107.2, 50.5, 43.8. ES-MS calcd. for 
C34H29N6O6S: [M+H]
+
 649.18; found 649.1. 
4-{4-[3'-(Morpholine-4-carbonyl)-biphenyl-4-yl]-[1,2,3]triazol-1-
ylmethyl}-3-nitro-benzoic acid 93j. Yield: 56%; 
1
H-NMR δ (300 MHz; 
CD3OD): 8.79 (1H, s), 8.58 (1H, s), 8.35 
(1H, d, J=8.09 Hz), 8.02 (2H, d, J=7.87 
Hz), 7.88 (1H, d, J=7.23 Hz), 7.79 (2H, 
d, J=7.89 Hz), 7.75 (1H, s), 7.65 (1H,t), 7.45 (1H, d, J=8.09 Hz), 7.33 (1H, d, 
J=7.23 Hz), 6.23 (2H, s), 4.16 (2H, t), 3.88 (2H, t), 3.48 (4H, m); 
13
C-NMR δ 
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135.4, 135.0, 134.2, 131.5, 130.2, 128.2, 127.8, 127.3, 126.3, 126.0, 125.8, 
125.0, 70.9, 50.9, 50.2. ES-MS calcd. for C27H24N5O6: [M+H]
+
 514.16; found 
514.2. 
4'-[1-(4-Carboxy-2-nitro-benzyl)-1H-[1,2,3]triazol-4-yl]-biphenyl-3-
carboxylic acid 93k. Yield: 45%; 
1
H-NMR δ (300 MHz; CD3OD): 8.77 (1H, 
s), 8.63 (1H, s), 8.38 (1H, s), 8.37 (1H, d, 
J=7.87 Hz), 8.08 (1H, d, J=7.23 Hz ), 8.04 
(1H, d, J=8.11 Hz), 8.09 (2H, d, J=7.23 
Hz), 7.89 (2H, d, J=7.89 Hz), 7.35 (2H, d, J=8.11 Hz), 6.22 (2H, s); 
13
C-NMR 
δ (75 MHz; CD3OD): 165.9, 165.3, 157.8, 147.9, 142.9, 141.9, 135.5, 131.1, 
130.2, 129.7, 129.2, 128.7, 127.5, 127.2, 126.0, 125.9, 122.2, 117.9, 114.3, 
113.3, 50.8. ES-MS calcd. for C23H17N4O6: [M+H]
+
 445.11; found 445.1. 
4-[4-(3',4',5'-trimethoxy-biphenyl-4-yl)-[1,2,3]triazol-1-ylmethyl]-3-nitro-
benzoic acid 93l. Yield: 71%; 
1
H-NMR δ (300 MHz; CD3OD): 8.79 (1H, s), 
8.56 (1H, s), 8.34 (1H, d, J=8.11 Hz), 8.00 
(2H, d, J=7.87 Hz), 7.81 (2H, d, J=7.89 
Hz), 7.31 (1H, d, J=7.89 Hz), 7.01 (2H, s), 
6.20 (2H, s), 4.01 (6H, s), 3.80 (3H, s); 
13
C-NMR δ (75 MHz; CD3OD): 165.7, 153.7, 147.9, 141.2, 137.7, 136.6, 
134.5, 130.3, 129.2, 129.0, 128.7, 127.6, 127.3, 126.0, 125.9, 122.2, 104.5, 
59.9, 55.5, 50.5. ES-MS calcd. for C25H23N4O7: [M+H]
+
 491.15; found 491.2. 
3-Nitro-4-[4-(4-thiophen-2-yl-phenyl)-[1,2,3]triazol-1-ylmethyl]-benzoic 
acid 93m. Yield: 54%; 
1
H-NMR δ (300 MHz; CD3OD): 8.75 (1H, s), 8.55 
(1H, s), 8.34 (1H, d, J=8.11 Hz), 7.92 (2H, d, 
J=7.87 Hz), 7.75 (2H, d, J=7.89 Hz), 7.51 (1H, d, 
J=7.89 Hz), 7.45 (1H, d, J=8.09 Hz), 7.27 (1H, , 
J=7.23 Hz), 7.12 (1H, d, J=8.11 Hz), 6.18 (2H, s); 
13
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CD3OD): 165.6, 157.1, 148.1, 141.5, 135.0, 134.2, 133.2, 131.7, 130.2, 128.2, 
127.8, 127.1, 126.6, 126.0, 125.6, 125.2, 122.2, 50.8. ES-MS calcd. for 
C20H15N4O4S: [M+H]
+
 407.07; found 407.0. 
4-[4-(4'-Methoxy-3'-morpholin-4-ylmethyl-biphenyl-4-yl)-[1,2,3]triazol-1-
ylmethyl]-3-nitro-benzoic acid 93n. Yield: 54%; 
1
H-NMR δ (300 MHz; 
CD3OD): 8.79 (1H, s), 8.56 (1H, s), 8.35 
(1H, d, J=8.09 Hz), 8.02 (2H, d, J=7.87 
Hz), 7.88 (1H, d, J=7.23 Hz), 7.79 (2H, d, 
J=7.89 Hz), 7.75 (1H, d, J=7.87 Hz), 7.33 
(1H, d, J=7.23 Hz), 6.23 (2H, s), 4.12 (2H, t), 4.5 (2H, s), 4.01 (3H, s), 3.82 
(2H, t), 3.45 (4H, m); 
13
C-NMR δ (75 MHz; CD3OD): 165.5, 158.8, 156.2, 
149.2, 138.1, 136.5, 136.1, 135.4, 134.2, 131.4, 130.2, 128.9, 128.5, 127.6, 
127.4, 126.7, 125.4, 122.5, 114.9, 71.1, 56.5, 56.1, 50.4, 49.8. ES-MS calcd. 
for C28H28N5O6: [M+H]
+
 530.20; found 530.2. 
 
7.2.9. Synthesis of benzoic acid 1-phenylsulfanylmethyl-1H-[1,2,3]triazol-4-
ylmethyl ester 61 
A mixture of compound 80 (0.3 equiv.) and 200 µL of benzoyl chloride in 2 
mL of dry DMF were refluxed overnight under nitrogen atmosphere. When 
TLC analysis indicated complete consumption of limiting reactant 80, the 
mixture was diluted with aqueous solution of HCl 1 N and extracted with ethyl 
acetate (3 x 10 mL). The organics were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude was purified by flash chromatography (10% 
diethyl ether/n-hexane to 40% diethyl ether/n-hexane). Yield: 78%; 
1
H-NMR δ 
(600 MHz; CD3OD): 8.02 (2H, dd, J=1.32, 8.33 
Hz), 7.96 (1H, s), 7.64 (1H, t), 5.50 (1H, t), 7.36 
(2H, dd, J=2.19, 7.89 Hz), 7.28-7.25 (4H, m), 5.80 
(2H, s), 5.40 (2H, s); 
13
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132.5, 131.8, 130.8, 128.9, 128.5, 128.1, 127.8, 123.6, 57.0, 53.3. ES-MS 
calcd. for C17H16N3O2S: [M+H]
+
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List of Abbreviations 
 
5-HETE     5-hydroxyeicosatetraenoic acid  
5-HPETE    5-hydroperoxyeicosatetraenoic acid  
CAP     chemical available for purchase 
COX     cyclooxygenase 
cPGES-2    cytosolic prostaglandin E2 synthase 
DBU     1,8-diazabicyclo[5.4.0]undec-7-ene  
DCM     dichlorometane 
DHP     dihydropyran 
DIC     N,N'-dicyclohexylcarbodiimide  
DIPEA     N,N-diisopropylethylamine 
DMF     N,N-dimethylformamide 
DMSO     dimethylsulfoxide  
ES-MS     electrospray mass spectrometry 
FLAP     5-lipoxygenase-activating protein  
GSH     tripeptide glutathione  
HMBC     heteronuclear multiple bond coherence 
HOBt     N-hydroxybenzotriazole   
HPLC     high-performance liquid chromatography 
HSQC     heteronuclear single quantum coherence 
HTS     high-throughput screening 
IL-1β     interleukin 1β 
LO     lipoxygenase  
LPS     lipo-polysaccharide 
LT     leukotriene   
MAPEG  membrane associated proteins involved in 
eicosanoid and glutathione metabolism  
MEM     metoxy-ethoxy-methyl-ether  
MGST     microsomal glutathione transferase 
mPGES-1    microsomal prostaglandin E2 synthase-1  
mPGES-2    microsomal prostaglandin E2 synthase-2  
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide  
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MW     microwaves 
NBS     N-bromosuccinimide 
NMR     nuclear magnetic resonance 
NSAID     non steroidal anti-inflammatory drug 
PAF     platelet activating factor  
PDB     protein data bank  
PG     prostaglandin 
PGES     prostaglandin E2 synthase 
PL     phospholipase  
PM     petrosaspongiolide M 
QM     quantum mechanic  
QSAR     quantitative structure activity relationship 
r.t.     room temperature 
SAID     steroidal anti-inflammatory drug 
SAR     structure activity relationship 
TBAB     tetrabutil-ammonium-bromide 
TEA     triethylamine  
TFA     trifluoroacetic  
THF     tetrahydrofuran 
THP     tetrahydropyran  
TIS     triisopropylsilane  
TLC     thin layer chromatography 
TNF-α     tumor necrosis factor-α  
Tx     thromboxane  
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